<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7150983</article-id><article-id pub-id-type="doi">10.3390/v12030276</article-id><article-id pub-id-type="publisher-id">viruses-12-00276</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Rongyuan</given-names></name><xref ref-type="aff" rid="af1-viruses-12-00276">1</xref></contrib><contrib contrib-type="author"><name><surname>Sheng</surname><given-names>Zizhang</given-names></name><xref ref-type="aff" rid="af2-viruses-12-00276">2</xref></contrib><contrib contrib-type="author"><name><surname>Sreenivasan</surname><given-names>Chithra C.</given-names></name><xref ref-type="aff" rid="af1-viruses-12-00276">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7263-8420</contrib-id><name><surname>Wang</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="af1-viruses-12-00276">1</xref><xref rid="c1-viruses-12-00276" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="af1-viruses-12-00276">1</xref><xref ref-type="aff" rid="af3-viruses-12-00276">3</xref><xref rid="c1-viruses-12-00276" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-viruses-12-00276"><label>1</label>Department of Biology and Microbiology, South Dakota State University, Brookings, SD 57007, USA; <email>rongyuan.gao@sdstate.edu</email> (R.G.); <email>chithra.sreenivasan@sdstate.edu</email> (C.C.S.)</aff><aff id="af2-viruses-12-00276"><label>2</label>Zuckerman Institute, Columbia University, New York, NY 10027, USA; <email>zs2248@columbia.edu</email></aff><aff id="af3-viruses-12-00276"><label>3</label>BioSNTR, Brookings, SD 57007, USA</aff><author-notes><corresp id="c1-viruses-12-00276"><label>*</label>Correspondence: <email>dan.wang@sdstate.edu</email> (D.W.); <email>feng.li@sdstate.edu</email> (F.L.)</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><volume>12</volume><issue>3</issue><elocation-id>276</elocation-id><history><date date-type="received"><day>24</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Influenza causes millions of cases of hospitalizations annually and remains a public health concern on a global scale. Vaccines are developed and have proven to be the most effective countermeasures against influenza infection. Their efficacy has been largely evaluated by hemagglutinin inhibition (HI) titers exhibited by vaccine-induced neutralizing antibodies, which correlate fairly well with vaccine-conferred protection. Contrarily, non-neutralizing antibodies and their therapeutic potential are less well defined, yet, recent advances in anti-influenza antibody research indicate that non-neutralizing Fc-effector activities, especially antibody-dependent cellular cytotoxicity (ADCC), also serve as a critical mechanism in antibody-mediated anti-influenza host response. Monoclonal antibodies (mAbs) with Fc-effector activities have the potential for prophylactic and therapeutic treatment of influenza infection. Inducing mAbs mediated Fc-effector functions could be a complementary or alternative approach to the existing neutralizing antibody-based prevention and therapy. This review mainly discusses recent advances in Fc-effector functions, especially ADCC and their potential role in influenza countermeasures. Considering the complexity of anti-influenza approaches, future vaccines may need a cocktail of immunogens in order to elicit antibodies with broad-spectrum protection via multiple protective mechanisms.</p></abstract><kwd-group><kwd>influenza</kwd><kwd>non-neutralizing monoclonal antibody</kwd><kwd>antibody-dependent cellular cytotoxicity (ADCC)</kwd><kwd>Fc effector activities</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-12-00276"><title>1. Introduction</title><p>Influenza viruses cause severe respiratory illness, leading to 290,000&#x02013;650,000 deaths annually worldwide as estimated by the World Health Organization (WHO) [<xref rid="B1-viruses-12-00276" ref-type="bibr">1</xref>]. Influenza viruses consist of four known genera, A, B, C, and D, which belong to the family <italic>Orthomyxoviridae</italic> [<xref rid="B2-viruses-12-00276" ref-type="bibr">2</xref>]. Of these four genera, influenza A virus causes the greatest mortality and is the most common cause of both seasonal and pandemic influenza outbreaks. Influenza B virus can cause seasonal influenza while the influenza C virus can infect children with mild respiratory symptoms. Little is known about the impact of recently discovered influenza D virus on human health [<xref rid="B3-viruses-12-00276" ref-type="bibr">3</xref>,<xref rid="B4-viruses-12-00276" ref-type="bibr">4</xref>]. </p><p>Hemagglutinin (HA) and neuraminidase (NA) are the two primary viral surface glycoproteins (<xref ref-type="fig" rid="viruses-12-00276-f001">Figure 1</xref>) involved in critical steps of the influenza life cycle. The trimeric HA protein is comprised of two domains: the head domain and the stalk domain. HA head domain contains the receptor binding site (RBS) that binds to sialic acids (SAs) on the susceptible cells to initiate the virus&#x02019; replication cycle. After the virus is endocytosed, the fusion peptide in the HA stalk was exposed to mediate the membrane fusion towards releasing viral ribonucleoprotein (RNP) complex into the cytoplasm and subsequently to the nucleus of infected cells [<xref rid="B2-viruses-12-00276" ref-type="bibr">2</xref>]. After the newly assembled influenza virus buds from the infected cell, HA on the virion still interacts with the SA receptors on the host cell membrane. The tetrameric NA spike functions to release the viral progeny through cleaving &#x003b1;-ketosidic linkage between the SA and an adjacent sugar residue [<xref rid="B5-viruses-12-00276" ref-type="bibr">5</xref>].</p><p>The HA and NA proteins are also highly immunogenic and antibodies targeting both glycoproteins can be isolated after natural infection or vaccination. Through binding to viral surface proteins HA and NA, antibodies can block the essential steps in the virus replication cycle, thereby limiting the spread of infection. Due to the host immune pressure and error-prone RNA polymerase, HA and NA are very plastic and display difference in antigenic properties. According to the antigenic difference, influenza A virus can divide into 18 HA (H1&#x02013;H18) and 11 NA (N1&#x02013;N11) subtypes [<xref rid="B6-viruses-12-00276" ref-type="bibr">6</xref>]. According to the Weekly U.S. Influenza Surveillance Report released by CDC, H1N1(pdm09) and B/Victoria lineage viruses are equally dominant and responsible for the majority of death cases during the 2019&#x02013;2020 influenza season [<xref rid="B7-viruses-12-00276" ref-type="bibr">7</xref>].</p><p>Vaccination is the best countermeasure to prevent and control influenza [<xref rid="B8-viruses-12-00276" ref-type="bibr">8</xref>]. Live attenuated, inactivated and recombinant HA vaccines are the three types of licensed seasonal influenza vaccines [<xref rid="B9-viruses-12-00276" ref-type="bibr">9</xref>]. These vaccines conferred considerable protection in combating influenza by inducing antibodies that target HA. However, their efficacy can be significantly reduced when novel viruses emerge, or when there is a mismatch between the vaccine strain and the circulating influenza strain [<xref rid="B8-viruses-12-00276" ref-type="bibr">8</xref>]. Therefore, the ultimate goal is to develop a universal vaccine that could confer long-lasting protection against multiple influenza strains, including the drifted seasonal influenza viruses and antigenically distinct viruses. Several approaches are employed to achieve that goal, such as stalk-based immunogen [<xref rid="B10-viruses-12-00276" ref-type="bibr">10</xref>], chimeric HA immunogen strategies [<xref rid="B11-viruses-12-00276" ref-type="bibr">11</xref>] and computationally optimized broadly reactive antigen (COBRA)-based vaccines [<xref rid="B12-viruses-12-00276" ref-type="bibr">12</xref>,<xref rid="B13-viruses-12-00276" ref-type="bibr">13</xref>]. Elicitation of antibodies exhibiting ADCC activities also contributes to the design of universal vaccines, which are thought to confer broad-spectrum protection [<xref rid="B14-viruses-12-00276" ref-type="bibr">14</xref>].</p><p>Previous antibody protective efficiency was measured by their capability to prevent HA binding via neutralization assay and hemagglutination inhibition assay [<xref rid="B14-viruses-12-00276" ref-type="bibr">14</xref>,<xref rid="B15-viruses-12-00276" ref-type="bibr">15</xref>], antibodies without these functions were less well defined. However, increasing evidence suggests that non-neutralizing antibodies (nnAbs) can confer protection via multiple mechanisms without disturbing virus entry or membrane fusion, such as activating complement, increasing phagocytosis, targeting internal viral proteins and eliciting fragment crystallizable (Fc)-effector functions [<xref rid="B16-viruses-12-00276" ref-type="bibr">16</xref>,<xref rid="B17-viruses-12-00276" ref-type="bibr">17</xref>,<xref rid="B18-viruses-12-00276" ref-type="bibr">18</xref>,<xref rid="B19-viruses-12-00276" ref-type="bibr">19</xref>]. Unlike neutralizing antibodies, nnAbs do not bind to the RBS in the HA head and fail to inhibit hemagglutination. Therefore, these antibodies demonstrate no detectable <italic>in vitro</italic> hemagglutination inhibition (HI) titer or neutralizing activity commonly considered as the benchmark standard of vaccine efficacy. Nonetheless, recent studies have validated that nnAbs can also contribute to the vaccine-elicited protection against influenza virus infection <italic>in vivo</italic> [<xref rid="B20-viruses-12-00276" ref-type="bibr">20</xref>,<xref rid="B21-viruses-12-00276" ref-type="bibr">21</xref>]. The protective mechanisms employed by nnAbs depend on the engagement with effector cells and consist of antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP). ADCP also assists in the elimination of virus-infected cells and protects against influenza virus infection in a mouse model [<xref rid="B22-viruses-12-00276" ref-type="bibr">22</xref>]. Importantly, these nnAbs can be induced by vaccination in humans [<xref rid="B18-viruses-12-00276" ref-type="bibr">18</xref>,<xref rid="B20-viruses-12-00276" ref-type="bibr">20</xref>,<xref rid="B23-viruses-12-00276" ref-type="bibr">23</xref>]. Jegaskanda et al. showed that ADCC-mediated antibodies (ADCC-Abs) can be induced from monovalent inactivated influenza A(H1N1) virus vaccine, high titers of ADCC-Abs can contribute to lower virus replication and reduced clinical symptoms [<xref rid="B20-viruses-12-00276" ref-type="bibr">20</xref>]. Zhong and colleagues demonstrated that both ADCC-Abs and neutralizing antibodies can be elicited by influenza vaccination [<xref rid="B23-viruses-12-00276" ref-type="bibr">23</xref>].</p><p>The mechanism of the antibody-triggered Fc-effector functions is well understood. The antibody Fc region interacts with the Fc&#x003b3;RIIIa (CD16a) on the surface of the Fc receptor-bearing cells, primarily natural killer cells (NK cells). After the antibodies bind to their target viral proteins, the combined interactions activate these effector cells. The C-terminal immunoreceptor tyrosine-based activation motif (ITAM) in effector cells is subsequently activated to stimulate the release of granzyme B and perforin by activating signal-transduction molecules and various pathways, such as calcium-dependent pathways and mitogen-activated protein kinase pathway (originally known as extracellular signal-regulated kinases pathway) [<xref rid="B24-viruses-12-00276" ref-type="bibr">24</xref>,<xref rid="B25-viruses-12-00276" ref-type="bibr">25</xref>]. Details of the signaling pathways initiated by Fc-Fc receptors (FcRs) have been extensively reviewed by Nimmerjahn et al [<xref rid="B26-viruses-12-00276" ref-type="bibr">26</xref>]. Perforins can produce pores in the virus-infected cell surface, allowing the entry of granzyme B that cleaves death substrate to initiate apoptosis [<xref rid="B27-viruses-12-00276" ref-type="bibr">27</xref>]. Together, these facilitate the elimination of influenza virus-infected cells [<xref rid="B28-viruses-12-00276" ref-type="bibr">28</xref>]. This Fc-receptor binding activity was also confirmed to confer protection in animal models in the absence of neutralizing antibodies [<xref rid="B29-viruses-12-00276" ref-type="bibr">29</xref>].</p><p>Multiple parameters impact the potency of Fc-effector functions. FcRs expression pattern in these cells affects the potency of Fc-effector functions. FcRs are divided into activating and inhibitory receptors based on whether the receptor-mediated signal activates the ITAM or the opposing immunoreceptor tyrosine-based inhibitory motif (ITIM). The magnitude of NK cell responses critically relies on the integration of signals transduced by ITAM and ITIM [<xref rid="B30-viruses-12-00276" ref-type="bibr">30</xref>]. Depending on the antibody isotype, these binding receptors can differ. Fc&#x003b3;R, Fc&#x003b5;R, and Fc&#x003b1;R can recognize Fc region of IgG, IgE, and IgA, respectively [<xref rid="B31-viruses-12-00276" ref-type="bibr">31</xref>]. Fc&#x003b3;Rs are the most well-studied FcRs. Different Fc&#x003b3;Rs can vary significantly from antibody binding affinity to ADCC induction [<xref rid="B32-viruses-12-00276" ref-type="bibr">32</xref>]. In human FcRs, Fc&#x003b3;RI(CD64), Fc&#x003b3;RIIa(CD32a), Fc&#x003b3;RIIc(CD32c), and Fc&#x003b3;RIIIa(CD16a) are activating receptors, while Fc&#x003b3;RIIb (CD32b) is the inhibitory receptor [<xref rid="B33-viruses-12-00276" ref-type="bibr">33</xref>]. It is worth noting that no inhibitory receptor is present on NK cells&#x02019; surface, only the activating receptor Fc&#x003b3;RIIIa is expressed [<xref rid="B26-viruses-12-00276" ref-type="bibr">26</xref>]. Without the intervention of Fc&#x003b3;RIIb as an inhibitory receptor to negatively regulate cell activation, NK cells serve as the predominant cells that can mediate potent ADCC responses <italic>in vivo</italic> [<xref rid="B28-viruses-12-00276" ref-type="bibr">28</xref>]. </p><p>Although mouse Fc&#x003b3;Rs and their counterparts in humans are named similarly, they may differ substantially in their expression pattern, antibody subclass binding affinities and <italic>in vivo</italic> dominant Fc&#x003b3;Rs [<xref rid="B29-viruses-12-00276" ref-type="bibr">29</xref>,<xref rid="B33-viruses-12-00276" ref-type="bibr">33</xref>]. Some Fc&#x003b3;Rs, such as Fc&#x003b3;RIIa, Fc&#x003b3;RIIc, and Fc&#x003b3;RIIIb, are expressed in human immune cells but not in mice cells [<xref rid="B34-viruses-12-00276" ref-type="bibr">34</xref>] and Fc&#x003b3;RIV is expressed in mice immune cells but not in human cells [<xref rid="B35-viruses-12-00276" ref-type="bibr">35</xref>]. Therefore, a transgenic mouse model consistently expressing human FcRs is needed when investigating human antibody-mediated Fc-effector functions and the human Fc&#x003b3;R contribution to antiviral response. Smith et al. generated a mouse model without any murine Fc&#x003b3;Rs and human Fc&#x003b3;Rs genes were inserted into the mouse genome to express functional human Fc&#x003b3;Rs [<xref rid="B36-viruses-12-00276" ref-type="bibr">36</xref>]. These human Fc&#x003b3;Rs were validated to mediate the cytotoxic effects of human IgG antibodies, providing a valuable platform for therapeutic IgG antibodies studies [<xref rid="B29-viruses-12-00276" ref-type="bibr">29</xref>].</p><p>Most therapeutic antibodies in development are IgG [<xref rid="B37-viruses-12-00276" ref-type="bibr">37</xref>]. IgG subclasses (IgG1, IgG2, IgG3, and IgG4 in humans) exhibited different binding affinities to Fc&#x003b3;Rs as they differ in primary sequence and the associated structure. Of the four IgG subclasses, IgG1, IgG2, and IgG4 are used clinically for therapeutic purposes [<xref rid="B38-viruses-12-00276" ref-type="bibr">38</xref>], while the extensive application of IgG3 may be hindered by the its short serum half-life [<xref rid="B39-viruses-12-00276" ref-type="bibr">39</xref>,<xref rid="B40-viruses-12-00276" ref-type="bibr">40</xref>]. Both IgG1 and IgG3 can mediate potent ADCC activity, while IgG2 and IgG4 have a poor ADCC function [<xref rid="B41-viruses-12-00276" ref-type="bibr">41</xref>].</p><p>Lastly, antibody glycosylation is essential for maintaining antibody structural conformation which is directly related to the potency of Fc-effector functions [<xref rid="B37-viruses-12-00276" ref-type="bibr">37</xref>,<xref rid="B42-viruses-12-00276" ref-type="bibr">42</xref>]. Many factors can affect glycosylation patterns, which include age, pregnancy and virus infection [<xref rid="B43-viruses-12-00276" ref-type="bibr">43</xref>,<xref rid="B44-viruses-12-00276" ref-type="bibr">44</xref>,<xref rid="B45-viruses-12-00276" ref-type="bibr">45</xref>]. However, the detailed mechanism of how antibody glycosylation impact Fc-effector functions remains unclear. It has been demonstrated that the reduced content of fucose can enhance ADCC activity [<xref rid="B46-viruses-12-00276" ref-type="bibr">46</xref>]. Various approaches, such as alpha-(1,6)-fucosyltransferase gene knockout, have been developed to manipulate antibody fucosylation to optimize ADCC activity [<xref rid="B47-viruses-12-00276" ref-type="bibr">47</xref>]. Glyco-engineering and protein engineering have emerged as the two main strategies to harness ADCC activity [<xref rid="B48-viruses-12-00276" ref-type="bibr">48</xref>].</p><p>Antibodies mediating Fc-effector activities were isolated and characterized in numerous studies, which suggest that these antibodies can play a critical role in tumor clearance [<xref rid="B25-viruses-12-00276" ref-type="bibr">25</xref>] and immunity to multiple pathogens such as human immunodeficiency virus (HIV) [<xref rid="B49-viruses-12-00276" ref-type="bibr">49</xref>,<xref rid="B50-viruses-12-00276" ref-type="bibr">50</xref>], Ebola [<xref rid="B51-viruses-12-00276" ref-type="bibr">51</xref>], dengue virus (DENV) [<xref rid="B52-viruses-12-00276" ref-type="bibr">52</xref>], West Nile virus (WNV) [<xref rid="B53-viruses-12-00276" ref-type="bibr">53</xref>] and influenza virus [<xref rid="B16-viruses-12-00276" ref-type="bibr">16</xref>,<xref rid="B17-viruses-12-00276" ref-type="bibr">17</xref>]. HIV infection remains a health issue on a global scale and vaccine candidates were developed to address this deteriorating issue. Currently, only one HIV vaccine, RV144, shows modest efficacy (31% efficacy) and this efficacy is not associated with neutralizing antibodies but with potent ADCC-Abs [<xref rid="B54-viruses-12-00276" ref-type="bibr">54</xref>,<xref rid="B55-viruses-12-00276" ref-type="bibr">55</xref>,<xref rid="B56-viruses-12-00276" ref-type="bibr">56</xref>,<xref rid="B57-viruses-12-00276" ref-type="bibr">57</xref>,<xref rid="B58-viruses-12-00276" ref-type="bibr">58</xref>]. </p></sec><sec id="sec2-viruses-12-00276"><title>2. Antibodies Induce ADCC Activities through Diverse Innate Effector Cells</title><p>As Fc-Fc&#x003b3;R interactions are required to induce ADCC, effector cells must express Fc&#x003b3;Rs on membrane surface to facilitate Fc binding. The NK cell is not the only cell type that has the Fc&#x003b3;RIIIa on the membrane, other Fc receptor-bearing cells, like neutrophils, monocytes/macrophages, granulocytes, and dendritic cells (DCs) may also play a crucial role in mediating ADCC or ADCP for viral infected cell clearance [<xref rid="B26-viruses-12-00276" ref-type="bibr">26</xref>,<xref rid="B59-viruses-12-00276" ref-type="bibr">59</xref>,<xref rid="B60-viruses-12-00276" ref-type="bibr">60</xref>]. Broadly neutralizing mAbs targeting HA-stalk can induce ADCP by neutrophils, which indicate the important role of neutrophils in viral clearance [<xref rid="B61-viruses-12-00276" ref-type="bibr">61</xref>,<xref rid="B62-viruses-12-00276" ref-type="bibr">62</xref>]. Ackerman et al. described a high-throughput flow cytometry-based assay to measure the phagocytic activity by using a monocytic cell line [<xref rid="B63-viruses-12-00276" ref-type="bibr">63</xref>]. In addition, Horner et al. reported the critical role of polymorphonuclear granulocyte in mediating ADCC activity in combating malignant diseases [<xref rid="B64-viruses-12-00276" ref-type="bibr">64</xref>].</p></sec><sec id="sec3-viruses-12-00276"><title>3. <italic>In Vitro</italic> Assays to Assess Antibody-Induced ADCC Activities</title><p>Since the discovery of the ADCC phenomenon in 1965 by Erna Moeller [<xref rid="B65-viruses-12-00276" ref-type="bibr">65</xref>], multiple assays have been developed to measure ADCC activity for different purposes and are extensively employed in vaccine study and drug discovery. To measure ADCC activities <italic>in vitro</italic>, virus-infected target cells, antibodies, and effector cells are needed. The various assays differ in the type of effector cells used or the way to measure the cytotoxicity, which have contributed to high variability among the assays. Considering the complex mechanism of ADCC, it remains questionable which assays are the most physiologically relevant to predict the <italic>in vivo</italic> efficacy [<xref rid="B56-viruses-12-00276" ref-type="bibr">56</xref>,<xref rid="B66-viruses-12-00276" ref-type="bibr">66</xref>].</p><sec id="sec3dot1-viruses-12-00276"><title>3.1. <sup>51</sup>Cr Release Assay</title><p>ADCC activity is measured indirectly by the release of <sup>51</sup>Chromium(<sup>51</sup>Cr) following lysis of virus-infected target cells in early studies [<xref rid="B67-viruses-12-00276" ref-type="bibr">67</xref>,<xref rid="B68-viruses-12-00276" ref-type="bibr">68</xref>,<xref rid="B69-viruses-12-00276" ref-type="bibr">69</xref>]. In this assay, the target cells are labeled with <sup>51</sup>Cr and subsequently incubated with the appropriate antibody. The quantity of <sup>51</sup>Cr released from the lysed cells is detected by a gamma counter as a correlate of ADCC activity [<xref rid="B69-viruses-12-00276" ref-type="bibr">69</xref>]. However, the biohazard problem of radioisotopes plus the test&#x02019;s low sensitivity restricts the wide application of this assay. For these reasons, nonradioactive assays with better sensitivity are later developed to assess ADCC activities [<xref rid="B70-viruses-12-00276" ref-type="bibr">70</xref>].</p></sec><sec id="sec3dot2-viruses-12-00276"><title>3.2. Target Cell Killing Assay</title><p>Flow cytometry-based ADCC assays are developed to measure ADCC activity by using different fluorescent dyes to differentiate living and dead cells [<xref rid="B70-viruses-12-00276" ref-type="bibr">70</xref>,<xref rid="B71-viruses-12-00276" ref-type="bibr">71</xref>]. In this assay, PKH-67 is used to label both live and dead target cells while dead target cells and effector cells are labeled with 7-amino actinomycin D (7-AAD). Instead of measuring reporter molecules released from target cells, this assay directly measures the lysed target cells. The quantification of lysed target cells is determined by measuring the double fluorescent dyes positive cells by flow cytometry. Target cell death in the absence of antibody is used as a background control. In 1990, Radosevic et al. reported their ADCC assay using different fluorochromes for cell staining with similar principles [<xref rid="B72-viruses-12-00276" ref-type="bibr">72</xref>]. Compared to other ADCC measurement assays, this flow cytometry-based assay has a number of advantages such as simplicity, sensitivity, and accessibility, which gains it popularity in many laboratories [<xref rid="B72-viruses-12-00276" ref-type="bibr">72</xref>].</p></sec><sec id="sec3dot3-viruses-12-00276"><title>3.3. NK Cell Activation Assay</title><p>NK cell activation assay is employed extensively to evaluate ADCC activities <italic>in vitro</italic> due to its high-throughput and precision [<xref rid="B16-viruses-12-00276" ref-type="bibr">16</xref>,<xref rid="B29-viruses-12-00276" ref-type="bibr">29</xref>,<xref rid="B57-viruses-12-00276" ref-type="bibr">57</xref>,<xref rid="B73-viruses-12-00276" ref-type="bibr">73</xref>,<xref rid="B74-viruses-12-00276" ref-type="bibr">74</xref>]. In this flow cytometry-based assay, recombinant proteins or virus-infected cells are coated in plates followed by the addition of antibody and peripheral blood mononuclear cells (or NK cell lines). Lysosomal-associated membrane protein-1 (LAMP-1 or CD107a) is a cell marker expressed on the NK surface and is employed in this assay to identify NK cells&#x02019; functional activities as the expression level of CD107a is highly correlated with cytokine secretion from activated NK cells [<xref rid="B75-viruses-12-00276" ref-type="bibr">75</xref>,<xref rid="B76-viruses-12-00276" ref-type="bibr">76</xref>]. Therefore, the potency of ADCC activities can be determined indirectly by measuring the activation marker CD107a expression on the NK cell surface. This assay has been widely used to assess ADCC activities evoked by antibodies against the influenza virus and HIV [<xref rid="B77-viruses-12-00276" ref-type="bibr">77</xref>,<xref rid="B78-viruses-12-00276" ref-type="bibr">78</xref>].</p></sec><sec id="sec3dot4-viruses-12-00276"><title>3.4. ADCC Reporter Bioassay</title><p>This bioluminescent reporter assay is designed to determine ADCC activities by the measurement of firefly luciferase expression in effector cells [<xref rid="B79-viruses-12-00276" ref-type="bibr">79</xref>]. A modified Jurkat stable cell line expressing Fc&#x003b3;RIIIa is used as effector cells and expresses firefly luciferase when activated by nuclear factor of activated T cells (NFAT)-response element during the time when Fc&#x003b3;Rs are bound by Fc portion of the antibody. This cell line is developed in a simple thaw-and-use format which reduces the high inter-assay variability and greatly increases the throughput. This commercially available assay has been employed to quantify ADCC activities against influenza infections [<xref rid="B17-viruses-12-00276" ref-type="bibr">17</xref>,<xref rid="B80-viruses-12-00276" ref-type="bibr">80</xref>,<xref rid="B81-viruses-12-00276" ref-type="bibr">81</xref>,<xref rid="B82-viruses-12-00276" ref-type="bibr">82</xref>,<xref rid="B83-viruses-12-00276" ref-type="bibr">83</xref>,<xref rid="B84-viruses-12-00276" ref-type="bibr">84</xref>]. </p></sec></sec><sec id="sec4-viruses-12-00276"><title>4. ADCC Induced by anti-HA Antibodies</title><sec id="sec4dot1-viruses-12-00276"><title>4.1. HA Stalk-Targeting mAbs Can Mediate Robust ADCC Activities</title><p>The HA stalk region, in contrast to the HA head region, is less immunogenic. The antigenic subdominance of HA stalk region may be due to the steric shielding of HA head domain, making it less accessible to the humoral immunity [<xref rid="B85-viruses-12-00276" ref-type="bibr">85</xref>]. Therefore, antibodies against the stalk region are not readily stimulated and detected in natural infection of humans. Nevertheless, low levels of stalk-specific B cells are detected in influenza patients [<xref rid="B86-viruses-12-00276" ref-type="bibr">86</xref>]. Furthermore, anti-stalk antibodies with broad neutralizing activity have been isolated and characterized [<xref rid="B87-viruses-12-00276" ref-type="bibr">87</xref>,<xref rid="B88-viruses-12-00276" ref-type="bibr">88</xref>,<xref rid="B89-viruses-12-00276" ref-type="bibr">89</xref>,<xref rid="B90-viruses-12-00276" ref-type="bibr">90</xref>,<xref rid="B91-viruses-12-00276" ref-type="bibr">91</xref>,<xref rid="B92-viruses-12-00276" ref-type="bibr">92</xref>]. Since the stalk domain is more conserved than the head domain, these antibodies exhibit broad-spectrum binding and are capable of conferring heterosubtypic protection by interfering with the membrane fusion. HA stalk antibodies were shown to neutralize subtypes in the same group or cross both group 1 and group 2 [<xref rid="B93-viruses-12-00276" ref-type="bibr">93</xref>,<xref rid="B94-viruses-12-00276" ref-type="bibr">94</xref>]. Ekiert et al. reported that HA stalk-binding human antibody, CR6261, neutralizes multiple influenza subtypes from group 1 [<xref rid="B95-viruses-12-00276" ref-type="bibr">95</xref>]. Corti et al. found that one antibody generated from single human plasma targeting fusion sub-domain of the HA stalk could bind and neutralize influenza A viruses from both group 1 and group 2 [<xref rid="B94-viruses-12-00276" ref-type="bibr">94</xref>]. Dreyfus et al. reported an HA stalk-binding antibody, CR9114, broad binding to influenza A and B HAs and the antibody was able to confer protection against not only influenza A virus infection, but also influenza B virus infection in mice [<xref rid="B89-viruses-12-00276" ref-type="bibr">89</xref>]. It should be noted that some antibodies targeting the stalk region are not highly potent when compared to those against the head region. This deficiency should be addressed in future studies.</p><p>Through inhibiting conformational changes essential to the membrane fusion, HA stalk-binding antibodies can disarm influenza virus infectivity [<xref rid="B96-viruses-12-00276" ref-type="bibr">96</xref>]. Headless HA and chimeric HA are the two strategies to elicit HA stalk-reactive antibodies [<xref rid="B86-viruses-12-00276" ref-type="bibr">86</xref>]. These stalk-reactive antibodies exhibit higher protective potency <italic>in vivo</italic> than <italic>in vitro</italic> since these antibodies may be capable of engaging Fc&#x003b3;R-bearing cells to confer Fc-dependent protection [<xref rid="B97-viruses-12-00276" ref-type="bibr">97</xref>]. Vries et al. showed that anti-H1 stalk ADCC-antibody can be detected after the immunization with a chimeric HA consisting of an H1 stalk domain and an irrelevant head domain [<xref rid="B21-viruses-12-00276" ref-type="bibr">21</xref>]. The incorporation of two anti-viral mechanisms has attracted substantial attention in influenza vaccine design. Those HA stalk vaccine candidates were tested in human clinical trials [<xref rid="B98-viruses-12-00276" ref-type="bibr">98</xref>,<xref rid="B99-viruses-12-00276" ref-type="bibr">99</xref>]. Unfortunately, clinical outcomes of HA stalk-based vaccines are not encouraging so further clinical study was recently discontinued, which emphasizes a critical need to discover novel vaccines that are capable of inducing potent cross-subtype protective antibodies with ADCC activity (<uri xlink:href="https://www.fiercebiotech.com/biotech/gsk-dumps-universal-flu-vaccine-after-interim-data-readout">https://www.fiercebiotech.com/biotech/gsk-dumps-universal-flu-vaccine-after-interim-data-readout</uri>). </p></sec><sec id="sec4dot2-viruses-12-00276"><title>4.2. HI-Negative Head-Targeting mAbs Can Mediate Robust ADCC Activities</title><p>The anti-stalk antibodies can induce ADCC activities through engaging Fc&#x003b3;Rs on NK cells, but the role of anti-HA head mAbs in inducing ADCC remains unclear. Dilillo et al. used an Fc&#x003b3;R knock-out mice model to show that only anti-HA stalk mAbs can bind to Fc&#x003b3;Rs and induce ADCC potently whereas anti-HA head mAbs inefficiently induce ADCC activity due to poor engagement of Fc&#x003b3;Rs on the NK cell surface [<xref rid="B29-viruses-12-00276" ref-type="bibr">29</xref>]. Other research groups also reported on these findings independently [<xref rid="B73-viruses-12-00276" ref-type="bibr">73</xref>,<xref rid="B83-viruses-12-00276" ref-type="bibr">83</xref>]. Interestingly, the examination of anti-HA head mAbs for mediating ADCC in different studies achieved distinct results. Recent studies suggested that some HA-head reactive antibodies (HI-negative) could also engage Fc&#x003b3;RIIIa on NK cells and mediate ADCC activity (<xref ref-type="fig" rid="viruses-12-00276-f002">Figure 2</xref>). </p><p>Firstly, epitopes in the vestigial esterase domain on HA head have also shown some promise as ADCC-Ab binding targets (<xref ref-type="fig" rid="viruses-12-00276-f002">Figure 2</xref>A). Vestigial esterase domain-binding antibodies were reported to function mainly by blocking viral egress similar to NA inhibitors [<xref rid="B89-viruses-12-00276" ref-type="bibr">89</xref>,<xref rid="B101-viruses-12-00276" ref-type="bibr">101</xref>]. Recent studies indicated that vestigial esterase domain-binding antibodies also elicit ADCC that may help to protect against viral infection [<xref rid="B102-viruses-12-00276" ref-type="bibr">102</xref>]. Bangaru and colleagues found a monoclonal antibody, H3v-47, that not only can neutralize diverse H3N2 viruses and block progeny viruses release, but also induce potent ADCC activity, suggesting that Fc-effector functions are critical for both HA head and stalk targeting antibodies [<xref rid="B102-viruses-12-00276" ref-type="bibr">102</xref>]. Interestingly, these researchers found that this multifunctional antibody can recognize a novel epitope that spans the vestigial esterase and receptor-binding subdomains. Similar Fc-mediated ADCC activity was observed in mAb 46B8 that targets the vestigial esterase domain of HA head of the influenza B virus [<xref rid="B74-viruses-12-00276" ref-type="bibr">74</xref>]. In addition, the vestigial esterase domain is highly conserved, indicating a potential role in universal vaccine design.</p><p>Secondly, antibodies targeting epitopes in the trimer interface may also initiate Fc-effector activities. Watanabe et al. reported that antibody (S5V2-29) binding to a conserved epitope at the HA head trimer interface can also confer potent protection <italic>in vivo</italic> by activating Fc&#x003b3;R-dependent effector activities [<xref rid="B103-viruses-12-00276" ref-type="bibr">103</xref>]. Bangaru et al. discovered a broadly protective antibody, FluA-20, which recognized a well-conserved epitope occluded in the trimer interface and also exhibited robust Fc-mediated ADCC <italic>in vitro</italic> [<xref rid="B104-viruses-12-00276" ref-type="bibr">104</xref>]. However, the ADCC may not be essential to the protective role in mice. Historically, it is believed that the trimeric HA protein is so stable that the trimer interface may not be exposed to the host immune system and is likely unreachable by antibody but, contrarily, the epitopes identified by these researchers suggest that the trimer interface may be accessible, at least partially. As such, the trimer interface can be further explored as a potential target for vaccine and therapeutics.</p><p>Thirdly, some HA-head reactive antibodies with undefined epitopes were reported to confer protection <italic>in vivo</italic> via Fc-effector functions. DiLillio et al. demonstrated that the broadly neutralizing HA head-reactive antibodies, 4G05 and 1F05, can induce protection <italic>in vivo</italic> through Fc-Fc&#x003b3;R interactions whereas strain-specific HA head reactive antibodies confer protection in an Fc-Fc&#x003b3;R interactions-independent manner <italic>in vivo</italic> [<xref rid="B100-viruses-12-00276" ref-type="bibr">100</xref>]. In addition, anti-H4 monoclonal antibodies binding to the HA head showed high cross-reactivity to avian and mammalian H4 HAs and protected mice from lethal H4N6 challenges through ADCC activity [<xref rid="B81-viruses-12-00276" ref-type="bibr">81</xref>]. Two highly conserved epitopes, designated E1 and E2, located in HA head of a pandemic H1N1 virus, were reported to be recognized by ADCC-Ab [<xref rid="B70-viruses-12-00276" ref-type="bibr">70</xref>]. The discovery of HA head reactive antibodies and conserved epitopes may assist the future design of universal vaccines and therapeutics.</p></sec><sec id="sec4dot3-viruses-12-00276"><title>4.3. HI-Positive Head-Targeting mAbs Cannot Mediate Robust ADCC Activities</title><p>As stated above, HA stalk-targeted monoclonal antibodies and HA head-targeted antibodies with no detectable HI titer may evoke potent ADCC activities both <italic>in vitro</italic> and <italic>in vivo</italic>. However, HI-positive antibodies that block RBS are commonly demonstrated not to induce robust ADCC activities [<xref rid="B82-viruses-12-00276" ref-type="bibr">82</xref>,<xref rid="B83-viruses-12-00276" ref-type="bibr">83</xref>,<xref rid="B105-viruses-12-00276" ref-type="bibr">105</xref>]. This failure in inducing potent ADCC activity by HI-positive antibodies might be explained by a model proposed by Leon and colleagues [<xref rid="B105-viruses-12-00276" ref-type="bibr">105</xref>]. In this model, two synapses between the effector cell and the virus-infected cells are essential for a robust ADCC response (<xref ref-type="fig" rid="viruses-12-00276-f003">Figure 3</xref>A,B). The binding between Fc and Fc&#x003b3;RIIIa serves as the first synapse and the interaction between viral HA head and the SA on the effector cell forms the second synapse. These two synapses cooperatively reinforce the connection between the target cell and the effector cell, which mediate robust ADCC activity. The Fc-Fc&#x003b3;RIIIa interaction alone is insufficient to induce potent ADCC activity and the interaction of HA to SA on the effector cell is required to induce potent ADCC function [<xref rid="B82-viruses-12-00276" ref-type="bibr">82</xref>,<xref rid="B83-viruses-12-00276" ref-type="bibr">83</xref>,<xref rid="B105-viruses-12-00276" ref-type="bibr">105</xref>]. However, it remains obscure whether the SA-binding of HA activates a signaling pathway to induce ADCC or stabilizes the interaction between antibody and innate immune leukocytes [<xref rid="B105-viruses-12-00276" ref-type="bibr">105</xref>]. HI-positive antibodies may compete with the SA on the effector cell in binding to the HA head domain, which as a result may impair the second synapse and hence lead to the reduced ADCC activity eventually (<xref ref-type="fig" rid="viruses-12-00276-f003">Figure 3</xref>C). It was reported that the <italic>in vitro</italic> ADCC activity induced by a stalk-reactive antibody is diminished after the addition of a HI-positive antibody [<xref rid="B83-viruses-12-00276" ref-type="bibr">83</xref>,<xref rid="B105-viruses-12-00276" ref-type="bibr">105</xref>]. The blocked or diminished ADCC activity may be due to the competitive role of neutralizing (HI-positive) antibody in binding to the HA. Vaccination can induce both neutralizing mAbs and nnAbs, future vaccine design should consider this delicate balance to achieve the optimal vaccine efficacy.</p><p>It is worth noting that neutralization and ADCC are not mutually exclusive. Antibodies with both anti-viral mechanisms have also been identified and characterized in recent studies, which demonstrated that ADCC activity could occur concurrently with a neutralization response [<xref rid="B23-viruses-12-00276" ref-type="bibr">23</xref>,<xref rid="B106-viruses-12-00276" ref-type="bibr">106</xref>]. Shen et al. reported that one HA head-targeted antibody, C12G6, can not only neutralize Yamagata, Victoria and earlier lineages of influenza B viruses, but also inhibits the membrane fusion, virus egress, and induces an ADCC response [<xref rid="B106-viruses-12-00276" ref-type="bibr">106</xref>]. Notably, they also demonstrated that the potency of C12G6-mediated ADCC activity against different viruses followed an opposite trend to its HI activity, in which higher HI titer was found to be associated with relatively lower ADCC activity, and vice versa.</p><fig id="viruses-12-00276-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Two synapses between effector cell and virus-infected cell are essential for robust ADCC activities. The interaction between Fc and Fc&#x003b3;RIIIa severs as the first synapse and the interaction between viral HA head and the sialic acid on effector cell form the second synapse, which are indispensable for inducing potent ADCC activities (<bold>A</bold>,<bold>B</bold>). The HI-positive antibody may interfere with the interaction between viral HA head and the sialic acid on effector cell, leading to weak ADCC activity (<bold>C</bold>). HI assay was extensively performed to determine the effects of antibodies in blocking the receptor engagement and replication of the viruses. However, this evaluation may be challenged by some emerging influenza viruses that lack the ability to agglutinate red blood cells of various animal origins [<xref rid="B107-viruses-12-00276" ref-type="bibr">107</xref>]. In this scenario, the cell-based virus-neutralization assay would be suitable for the characterization of RBS binding antibodies.</p></caption><graphic xlink:href="viruses-12-00276-g003"/></fig></sec></sec><sec id="sec5-viruses-12-00276"><title>5. ADCC to Other Proteins in Influenza Virus</title><p>Three influenza proteins are expressed on the viral membrane; HA, NA, and the Matrix 2 protein (M2) and are targets for ADCC-Abs (<xref ref-type="fig" rid="viruses-12-00276-f004">Figure 4</xref>). Although still critical in the viral life cycle, compared to HA, NA and M2 proteins have relatively lower expression on the viral surface and are not heavily targeted by the immune response. For this reason, NA and M2 are similarly less immunogenic and have a slower antigenic drift rate. This makes them attractive vaccine targets and recently more studies have been exploring this avenue [<xref rid="B108-viruses-12-00276" ref-type="bibr">108</xref>,<xref rid="B109-viruses-12-00276" ref-type="bibr">109</xref>,<xref rid="B110-viruses-12-00276" ref-type="bibr">110</xref>].</p><p>The NA functions to cleave host SA receptors in the viral life cycle allowing the release of nascent viruses and NA-targeted mAbs have shown a protective effect in animal models by blocking this release mechanism [<xref rid="B111-viruses-12-00276" ref-type="bibr">111</xref>]. Antibodies targeting NA are induced at lower level than antibodies targeting HA after vaccination, which may be due to the relatively less expression of NA on infected cells [<xref rid="B112-viruses-12-00276" ref-type="bibr">112</xref>]. Some NA-targeted antibodies require Fc-Fc&#x003b3;R interactions to induce protection [<xref rid="B18-viruses-12-00276" ref-type="bibr">18</xref>,<xref rid="B112-viruses-12-00276" ref-type="bibr">112</xref>]. DiLillio et al. reported that the broadly neutralizing NA-reactive antibodies, 3C05, can induce protective immunity <italic>in vivo</italic> in an Fc&#x003b3;R-dependent manner [<xref rid="B100-viruses-12-00276" ref-type="bibr">100</xref>]. Recently, Stadlbauer et al. showed that one monoclonal antibody generated from plasmablasts isolated from a human donor naturally infected with the H3N2 virus, designated 1G01, showed the broadest reactive spectrum to a variety of neuraminidases ranging from influenza A group 1 and group 2, to both influenza B virus lineages [<xref rid="B113-viruses-12-00276" ref-type="bibr">113</xref>]. These antibodies exhibited multiple anti-viral activities including the blockade of virus particle release and ADCC. The combination of two anti-viral mechanisms contributed to the broad protection from lethal challenges <italic>in vivo</italic> by these antibodies targeting neuraminidase antigen. </p><p>The M2 conducts the proton flux into the virion in the process of virus entry and equilibrates pH across the trans-Golgi network in the viral maturation stage [<xref rid="B114-viruses-12-00276" ref-type="bibr">114</xref>,<xref rid="B115-viruses-12-00276" ref-type="bibr">115</xref>]. Response against epitopes from the ectodomain of M2 (M2e) has been shown to induce protective immunity in mice [<xref rid="B116-viruses-12-00276" ref-type="bibr">116</xref>]. M2e raises the hope for the universal vaccine because of its highly conserved sequence and antibodies targeting M2e with broad protective effects in animal models [<xref rid="B117-viruses-12-00276" ref-type="bibr">117</xref>,<xref rid="B118-viruses-12-00276" ref-type="bibr">118</xref>]. M2e vaccine candidates with universal vaccine potential are tested in clinical studies [<xref rid="B109-viruses-12-00276" ref-type="bibr">109</xref>]. It is worth noting that mAbs targeting the M2e are believed to possess Fc-receptor dependent functions, like ADCC or ADCP [<xref rid="B109-viruses-12-00276" ref-type="bibr">109</xref>,<xref rid="B119-viruses-12-00276" ref-type="bibr">119</xref>,<xref rid="B120-viruses-12-00276" ref-type="bibr">120</xref>,<xref rid="B121-viruses-12-00276" ref-type="bibr">121</xref>]. Song et al. generated an M2e-targeted mAb (Z3G1) without detectable neutralizing activity. Interestingly, the Z3G1 antibody was found to be able to induce potent ADCC and CDC activities <italic>in vitro</italic> as well as demonstrated protective effect <italic>in vivo</italic> [<xref rid="B122-viruses-12-00276" ref-type="bibr">122</xref>]. Bakkouri et al. further demonstrated the essential role of Fc receptors in anti-M2e antibody-induced protection in mice [<xref rid="B117-viruses-12-00276" ref-type="bibr">117</xref>]. These studies indicate that M2e-based vaccines evoke cross-protective responses in an Fc&#x003b3;R-dependent manner. Generation and characterization of mAbs against M2e can provide critical insights for the development of novel therapeutics against influenza virus infection. </p><p>In addition to those proteins expressed on the viral surface, influenza nucleoprotein (NP) possesses highly conserved regions and is also detected on influenza virus-infected host cells surface [<xref rid="B123-viruses-12-00276" ref-type="bibr">123</xref>,<xref rid="B124-viruses-12-00276" ref-type="bibr">124</xref>]. This makes NP reachable by antibody and substantial efforts have been focused on the antiviral effects of anti-NP mAbs. The host immune response against NP may participate in multi-mechanisms against influenza infection. Cytotoxic T lymphocytes (CTL) can kill target cells via the recognition of NP antigen peptides presented by MHC-I molecules [<xref rid="B125-viruses-12-00276" ref-type="bibr">125</xref>,<xref rid="B126-viruses-12-00276" ref-type="bibr">126</xref>]. Berthoud et al. reported a T cell-inducing vaccine based on NP and M1, was safe and immunogenic in older adults [<xref rid="B127-viruses-12-00276" ref-type="bibr">127</xref>]. These internal viral proteins have not only shown beneficial by inducing host CTL response, but also can serve as a target for protective mAbs. Jegaskanda et al. demonstrated that mAbs targeting M1 and NP can also elicit ADCC activity and these mAbs can be induced by influenza vaccination and natural infection in children [<xref rid="B20-viruses-12-00276" ref-type="bibr">20</xref>,<xref rid="B128-viruses-12-00276" ref-type="bibr">128</xref>]. However, the protective role of anti-NP ADCC-Abs has not been investigated in animal models. Since internal viral proteins are more conserved, these ADCC-Abs may be considered to be included in future universal vaccine design.</p></sec><sec id="sec6-viruses-12-00276"><title>6. ADCC-Based Vaccine</title><p>To tackle the threat posed by influenza viruses, developing a universal vaccine that can induce broad immune response against both seasonal drift strains and emerging strains with pandemic potential is of heightening priority of influenza research. Considerable effort has been focused on the development of therapeutic agents and universal vaccines against influenza virus infection in recent decades. Protective antibodies that bind to conserved epitopes in the HA head, HA stalk, NA, NP, M2e have been isolated and characterized in the vaccine research. Most influenza vaccinology studies aim to induce a high titer of broad neutralizing antibodies (bnAbs), which are capable of conferring broad and durable protection against influenza virus infection, but nnAbs are less investigated. However, it is difficult to induce bnAbs through natural infection and the effectiveness of bnAbs was compromised after the emergence of mutant viruses. Therefore, nnAb has become an alternative option and numerous studies have shown the different protective mechanisms of nnAbs and bnAbs [<xref rid="B16-viruses-12-00276" ref-type="bibr">16</xref>,<xref rid="B20-viruses-12-00276" ref-type="bibr">20</xref>,<xref rid="B129-viruses-12-00276" ref-type="bibr">129</xref>]. Although no neutralizing activities can be detected <italic>in vitro</italic>, nnAbs are competent to mediate Fc-dependent protection <italic>in vivo</italic> by eliciting Fc-dependent effector activities. The protective property exhibited by nnAb seems to make an equally potential candidate for universal vaccines and therapeutics against influenza infection. Therefore, Fc-dependent effector activities should be considered and recognized when we evaluate the protective effects of influenza therapeutic agents and vaccine candidates.</p><p>The ADCC activity serves as a protective mechanism of HA stalk-binding antibodies and ADCC-Abs also exhibit much greater cross-reactivity than classic neutralizing antibodies, defining a promising direction to universal influenza vaccines. Various animal models are used to assess the protective capacity of ADCC based vaccines, including mouse, ferret, and non-human primates. Florek et al. reported that the ADCC-Abs induced by vaccination are capable of inhibiting influenza virus shedding in cynomolgus macaques [<xref rid="B130-viruses-12-00276" ref-type="bibr">130</xref>]. A study focusing on severe human infection cases in China and Australia suggested that antibodies from severe influenza survivors were more likely to exhibit potent ADCC activity, which highlights critical role of ADCC in combating influenza virus infections [<xref rid="B131-viruses-12-00276" ref-type="bibr">131</xref>]. </p><p>ADCC represents a promising strategy for vaccine development, but there are still several questions to be addressed. First, the pre-existing neutralizing antibodies may affect the efficacy of the ADCC-based vaccine. He et al reported that the HI-positive antibody can inhibit the potency of ADCC activity induced by HA stalk-specific antibodies by competing in HA binding [<xref rid="B83-viruses-12-00276" ref-type="bibr">83</xref>]. Therefore, the efficacy of the ADCC-based vaccine may be affected by pre-existing immunity. Besides, the activation of pre-existing B cells may induce class switching from IgG to non-ADCC isotypes [<xref rid="B132-viruses-12-00276" ref-type="bibr">132</xref>]. Second, vaccines that elicit antibodies targeting the M2 or the internal proteins may confer protection against severe influenza diseases, however, may not prevent viral infection since these antibodies mainly recognize proteins expressed on the infected cell membrane [<xref rid="B99-viruses-12-00276" ref-type="bibr">99</xref>]. Third, whether sufficient ADCC-Abs can be induced by vaccination is unclear. The antigen needs to be carefully designed and inclusion of an adjuvant is also critical to protective outcome. Four, there are reports of antibody-dependent enhancement (ADE) in ADCC-mediating antibodies [<xref rid="B71-viruses-12-00276" ref-type="bibr">71</xref>,<xref rid="B133-viruses-12-00276" ref-type="bibr">133</xref>]. In these studies, ADCC epitopes were identified and these epitope-based vaccines were generated and tested in mice. The immunized animals with ADCC epitopes showed robust ADCC activities but had lower survival rates in comparison with the control group. In addition, it was shown that ADCC epitope-based vaccines might have side effects including extra tissue damage as seen in the lungs, which was caused by the high level of cytotoxic granules (perforin) induced by ADCC activation [<xref rid="B71-viruses-12-00276" ref-type="bibr">71</xref>].</p></sec><sec id="sec7-viruses-12-00276"><title>7. Strategies to Augment ADCC Activity</title><p>Augmenting ADCC activity is a novel research direction in cancer research. Target cell killing activities triggered by ADCC mAbs can be substantially increased by the addition of ADCC-promoting agents, which has attracted substantial attention in cancer research [<xref rid="B134-viruses-12-00276" ref-type="bibr">134</xref>,<xref rid="B135-viruses-12-00276" ref-type="bibr">135</xref>]. Means of augmentation of these responses in cancer research might shed light on influenza research as well. Different strategies for enhancing ADCC were developed and employed in clinical trials in recent studies.</p><p>Considering Fc- Fc&#x003b3;RIII interaction is required to elicit ADCC activities, the potency of ADCC can be improved by strengthening this interaction. By selecting Fc variants with optimized Fc-Fc&#x003b3;RIII affinity, antibodies can elicit a more robust activating signal to the effector cells [<xref rid="B59-viruses-12-00276" ref-type="bibr">59</xref>]. Lazar et al. report that Fc variant S239D/I332E has the capacity to optimize Fc-Fc&#x003b3;R interaction and enhance effector function both <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="B136-viruses-12-00276" ref-type="bibr">136</xref>].</p><p>Other strategies have been attempted to promote the secretion of cytokines by activating effector cells. Reovirus and toll-like receptor (TLR) agonists can increase NK-mediated ADCC by facilitating cytokines secretion [<xref rid="B137-viruses-12-00276" ref-type="bibr">137</xref>]. TLR agonists can significantly enhance ADCC by increasing the percentage of activated NK cells. It has been reported that CpG-containing oligodeoxynucleotides (CpG ODN), TLR9 agonists, have the effect of promoting the cytokines secretion from an activated NK cell [<xref rid="B138-viruses-12-00276" ref-type="bibr">138</xref>].</p></sec><sec sec-type="conclusions" id="sec8-viruses-12-00276"><title>8. Conclusions and Future Directions</title><p>The protective efficacy of influenza vaccines largely depends on the stimulation of neutralizing antibodies. For a long period of time, vaccine efficacy has been evaluated by HI titers of neutralizing antibodies, which correlate fairly well with traditional views on vaccine-conferred protection. Recently it is becoming increasingly apparent that nnAbs also play a critical role in combating influenza infection even though <italic>in vitro</italic> antiviral activity is not detected in traditional assays [<xref rid="B16-viruses-12-00276" ref-type="bibr">16</xref>,<xref rid="B17-viruses-12-00276" ref-type="bibr">17</xref>,<xref rid="B18-viruses-12-00276" ref-type="bibr">18</xref>]. Therefore, future evaluation of vaccine efficacy should take Fc-dependent antiviral functions into consideration to optimize vaccine efficacy. In this review, we have summarized multiple anti-viral mechanisms of monoclonal antibodies with ADCC function and reveal that ADCC can overlap substantially with other mechanisms to confer heterosubtypic protection against seasonal and pandemic influenza. The characterization of identified nnAbs constitutes a novel pathway that mayraise hope for the design of universal vaccines. However, there are still questions about ADCC-Abs need to be addressed.</p><list list-type="simple"><list-item><label>(1)</label><p>As mAbs mediated Fc-effector activities are epitope dependent, identifying epitopes that can elicit nnAbs will serve as a good start for the rational design of universal vaccines and therapeutics. Some studies show that ADCC-Abs recognize linear epitopes [<xref rid="B70-viruses-12-00276" ref-type="bibr">70</xref>]. Arunkumar et al. demonstrated that antibodies recognizing conformational epitopes exhibit better protection compared to the antibodies targeting linear epitopes [<xref rid="B17-viruses-12-00276" ref-type="bibr">17</xref>]. Further investigation should be focused on the elucidation of which epitope type can induce a more potent ADCC response and as a result provide better protection.</p></list-item><list-item><label>(2)</label><p>ADCC-Abs may also exert immune pressure on the virus, resulting in escape mutants that evade antibody recognition similar to what is seen with traditional neutralizing antibodies. No influenza studies have reported ADCC-antibody escape mutants currently, but Chung et al. demonstrated the critical amino acids in the linear epitope could mutate to escape ADCC responses in HIV-1 [<xref rid="B139-viruses-12-00276" ref-type="bibr">139</xref>]. Lee et al. summarized two potential mechanisms employed by HIV-1 to resist ADCC responses, i. by directly reducing envelope antigen expression on the infected cell surface and ii. by restricting the exposure of epitopes on the envelope to reduce antibody binding [<xref rid="B56-viruses-12-00276" ref-type="bibr">56</xref>,<xref rid="B140-viruses-12-00276" ref-type="bibr">140</xref>,<xref rid="B141-viruses-12-00276" ref-type="bibr">141</xref>]. Similar or different scenarios may present in influenza, which may need further exploration in future studies.</p></list-item><list-item><label>(3)</label><p>It remains unclear about the viral replication step(s) in which ADCC occurs. It is indicated that ADCC activity does not intervene in viral entry and fusion and there is a high possibility that ADCC may target the virus-infected cell, which has HA, or other virus protein expressed [<xref rid="B142-viruses-12-00276" ref-type="bibr">142</xref>]. This should be better investigated.</p></list-item><list-item><label>(4)</label><p>Designing antibodies with enhanced capacity to induce ADCC activities against influenza infection should be pursued vigorously. As stated above, new approaches are being developed to augment ADCC in cancer research. These studies in cancer research may provide valuable insights into influenza research towards developing better vaccines or therapeutics to improve influenza patient outcomes. Therefore, it would be beneficial to measure the ADCC potency threshold for protective immunity. However, it is worth noting that a more potent ADCC response may not guarantee better protection. Arunkumar et at. reported that two non-neutralizing antibodies, KL-BHA-9B9 and KL-BHA-4C10, exhibited uncorrelated ADCC activity with <italic>in vivo</italic> protection [<xref rid="B17-viruses-12-00276" ref-type="bibr">17</xref>]. KL-BHA-9B9 had potent ADCC activity <italic>in vitro</italic> but poor protection <italic>in vivo</italic>, whereas KL-BHA-4C10 conferred strong protection <italic>in vivo</italic> but had almost undetectable ADCC <italic>in vitro</italic>. A better understanding of ADCC activation may facilitate the mechanistic elucidation of this phenomenon as well as other variabilities emerged in current assays.</p></list-item><list-item><label>(5)</label><p>Although diverse assays have been developed to measure ADCC activity <italic>in vitro</italic>, it is still obscure to what extent these assays can correlate to the efficacy <italic>in vivo</italic>. It is challenging to predict ADCC-Ab efficacy in humans. The transgenic mouse model expresses human Fc&#x003b3;Rs may better evaluate the antibody therapeutic effect in humans. However, mice are not natural hosts of influenza and influenza viruses causing human epidemics or pandemics typically replicate inefficiently in this animal model unless adapted viruses are used. Non-human primate models such as rhesus macaques or cynomolgus macaques are used in ADCC-Abs research and research findings from this model collectively indicated that ADCC-Abs are associated with reduced shedding of influenza viruses [<xref rid="B16-viruses-12-00276" ref-type="bibr">16</xref>,<xref rid="B130-viruses-12-00276" ref-type="bibr">130</xref>]. Considering the different expression patterns of Fc&#x003b3;Rs in humans and non-human primate animals, it remains uncertain whether the correlation of treatment outcome can be expected in humans. In this regard, clinical studies regarding ADCC-Abs are instrumental to examine the potential role of ADCC-Abs in combating influenza virus infection in humans [<xref rid="B143-viruses-12-00276" ref-type="bibr">143</xref>].</p></list-item><list-item><label>(6)</label><p>It would be interesting and worthwhile to study the synergy between neutralizing antibody and non-neutralizing antibody <italic>in vivo</italic> since both classes of antibodies will be elicited after viral infection. The high complexity of each type of antibodies and the lack of an ideal animal model make this investigation relatively challenging. In some cases, the Fc-effector functions induced by nnAb can increase the potency of neutralizing antibodies [<xref rid="B14-viruses-12-00276" ref-type="bibr">14</xref>]. In contrast, it is also revealed that Fc-effector functions may not play any role when there is a high dose of neutralizing antibodies [<xref rid="B29-viruses-12-00276" ref-type="bibr">29</xref>]. One possible explanation for this is that the function elicited by neutralizing antibodies, such as viral entry blocking or fusion disruption, is potent and sufficient for <italic>in vivo</italic> protection alone.</p></list-item><list-item><label>(7)</label><p>The interplay among ADCC-Abs targeting HA, NA, M2e and NP needs to be investigated. It is critical to identify what antibody combination patterns can induce synergistic protection to augment vaccine efficacy. It is reported that the NA-inhibiting antibody elicited weak ADCC response alone, but it may cooperate with antibodies targeting the HA stem to enhance their potency of ADCC activity [<xref rid="B83-viruses-12-00276" ref-type="bibr">83</xref>]. NA inhibitors can enhance Fc-dependent functions induced by anti-stalk antibody, suggesting a therapeutic synergy between NA inhibitors and anti-stalk antibody in humans [<xref rid="B144-viruses-12-00276" ref-type="bibr">144</xref>]. Deng et al. demonstrated that the vaccination with double-layered nanoparticles containing HA-stalk and M2e induced potent long-lasting immunity and full protection against divergent influenza A viruses challenge in mice, indicating that the combination of antibodies targeting HA stalk domain and M2e can improve the potency and breadth of vaccine-induced protection [<xref rid="B145-viruses-12-00276" ref-type="bibr">145</xref>]. The cocktail of therapeutic antibodies may overcome the emergence of viral escape mutants [<xref rid="B37-viruses-12-00276" ref-type="bibr">37</xref>]. Further studies on antibody or inhibitor interplay may guide the better design of future universal anti-influenza countermeasures with broad-spectrum protection via multiple mechanisms.</p></list-item></list></sec></body><back><ack><title>Acknowledgments</title><p>We thank Ian Hauffe for proofreading this manuscript and other members of the Li and Wang laboratories for their input into this work.</p></ack><notes><title>Author Contributions</title><p>Concept and design: D.W. and F.L.; literature search and writing: R.G. and C.C.S.; illustrations: R.G., Z.S. and D.W.; supervision and editing: D.W. and F.L.; final approval of the version submitted: all the authors. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was partially supported by NIH grant R01AI141889, by South Dakota State University agricultural experiment station (AES) 3AH-477, by National Science Foundation/EPSCoR (<uri xlink:href="http://www.nsf.gov/od/iia/programs/epscor/index.jsp">http://www.nsf.gov/od/iia/programs/epscor/index.jsp</uri>) award IIA1335423, and by the state of South Dakota&#x02019;s Governor&#x02019;s Office of Economic Development as a South Dakota Research Innovation Center.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-12-00276"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Up to 650,000 People Die of Respiratory Diseases Linked to Seasonal Flu Each Year</source><publisher-name>WHO</publisher-name><publisher-loc>Ginevra, Switzerland</publisher-loc><year>2017</year></element-citation></ref><ref id="B2-viruses-12-00276"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvier</surname><given-names>N.M.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>The biology of influenza viruses</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><issue>Suppl. 4</issue><fpage>D49</fpage><lpage>D53</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.039</pub-id><?supplied-pmid 19230160?><pub-id pub-id-type="pmid">19230160</pub-id></element-citation></ref><ref id="B3-viruses-12-00276"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hause</surname><given-names>B.M.</given-names></name><name><surname>Collin</surname><given-names>E.A.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Sheng</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Nelson</surname><given-names>E.A.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Characterization of a novel influenza virus in cattle and Swine: Proposal for a new genus in the Orthomyxoviridae family</article-title><source>MBio</source><year>2014</year><volume>5</volume><fpage>e00031-14</fpage><pub-id pub-id-type="doi">10.1128/mBio.00031-14</pub-id><?supplied-pmid 24595369?><pub-id pub-id-type="pmid">24595369</pub-id></element-citation></ref><ref id="B4-viruses-12-00276"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hause</surname><given-names>B.M.</given-names></name><name><surname>Ducatez</surname><given-names>M.</given-names></name><name><surname>Collin</surname><given-names>E.A.</given-names></name><name><surname>Ran</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Sheng</surname><given-names>Z.</given-names></name><name><surname>Armien</surname><given-names>A.</given-names></name><name><surname>Kaplan</surname><given-names>B.</given-names></name><name><surname>Chakravarty</surname><given-names>S.</given-names></name><name><surname>Hoppe</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003176</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003176</pub-id><?supplied-pmid 23408893?><pub-id pub-id-type="pmid">23408893</pub-id></element-citation></ref><ref id="B5-viruses-12-00276"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shtyrya</surname><given-names>Y.A.</given-names></name><name><surname>Mochalova</surname><given-names>L.V.</given-names></name><name><surname>Bovin</surname><given-names>N.V.</given-names></name></person-group><article-title>Influenza virus neuraminidase: Structure and function</article-title><source>Acta Nat.</source><year>2009</year><volume>1</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.32607/20758251-2009-1-2-26-32</pub-id></element-citation></ref><ref id="B6-viruses-12-00276"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Bourgeois</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Recuenco</surname><given-names>S.</given-names></name><name><surname>Gomez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>New world bats harbor diverse influenza A viruses</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003657</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003657</pub-id><pub-id pub-id-type="pmid">24130481</pub-id></element-citation></ref><ref id="B7-viruses-12-00276"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>CDC</collab><name><surname>Weekly</surname><given-names>U.S.</given-names></name></person-group><source>Influenza Surveillance Report</source><comment>Key Updates for Week 7, Ending 15 February</comment><publisher-name>CDC</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B8-viruses-12-00276"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houser</surname><given-names>K.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Influenza vaccines: Challenges and solutions</article-title><source>Cell Host Microbe</source><year>2015</year><volume>17</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.02.012</pub-id><pub-id pub-id-type="pmid">25766291</pub-id></element-citation></ref><ref id="B9-viruses-12-00276"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grohskopf</surname><given-names>L.A.</given-names></name><name><surname>Alyanak</surname><given-names>E.</given-names></name><name><surname>Broder</surname><given-names>K.R.</given-names></name><name><surname>Walter</surname><given-names>E.B.</given-names></name><name><surname>Fry</surname><given-names>A.M.</given-names></name><name><surname>Jernigan</surname><given-names>D.B.</given-names></name></person-group><article-title>Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2019&#x02013;2020 Influenza Season</article-title><source>MMWR Recomm. Rep.</source><year>2019</year><volume>68</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr6803a1</pub-id></element-citation></ref><ref id="B10-viruses-12-00276"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margine</surname><given-names>I.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Hai</surname><given-names>R.</given-names></name><name><surname>Heaton</surname><given-names>N.S.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Andrews</surname><given-names>S.A.</given-names></name><name><surname>Runstadler</surname><given-names>J.A.</given-names></name><name><surname>Wilson</surname><given-names>P.C.</given-names></name><name><surname>Albrecht</surname><given-names>R.A.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>10435</fpage><lpage>10446</lpage><pub-id pub-id-type="doi">10.1128/JVI.01715-13</pub-id><pub-id pub-id-type="pmid">23903831</pub-id></element-citation></ref><ref id="B11-viruses-12-00276"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Pica</surname><given-names>N.</given-names></name><name><surname>Hai</surname><given-names>R.</given-names></name><name><surname>Margine</surname><given-names>I.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>6542</fpage><lpage>6550</lpage><pub-id pub-id-type="doi">10.1128/JVI.00641-13</pub-id><pub-id pub-id-type="pmid">23576508</pub-id></element-citation></ref><ref id="B12-viruses-12-00276"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giles</surname><given-names>B.M.</given-names></name><name><surname>Ross</surname><given-names>T.M.</given-names></name></person-group><article-title>A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>3043</fpage><lpage>3054</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.100</pub-id><pub-id pub-id-type="pmid">21320540</pub-id></element-citation></ref><ref id="B13-viruses-12-00276"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>D.M.</given-names></name><name><surname>Darby</surname><given-names>C.A.</given-names></name><name><surname>Lefoley</surname><given-names>B.C.</given-names></name><name><surname>Crevar</surname><given-names>C.J.</given-names></name><name><surname>Alefantis</surname><given-names>T.</given-names></name><name><surname>Oomen</surname><given-names>R.</given-names></name><name><surname>Anderson</surname><given-names>S.F.</given-names></name><name><surname>Strugnell</surname><given-names>T.</given-names></name><name><surname>Cortes-Garcia</surname><given-names>G.</given-names></name><name><surname>Vogel</surname><given-names>T.U.</given-names></name><etal/></person-group><article-title>Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>4720</fpage><lpage>4734</lpage><pub-id pub-id-type="doi">10.1128/JVI.03152-15</pub-id><?supplied-pmid 26912624?><pub-id pub-id-type="pmid">26912624</pub-id></element-citation></ref><ref id="B14-viruses-12-00276"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Reading</surname><given-names>P.C.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name></person-group><article-title>Influenza-specific antibody-dependent cellular cytotoxicity: Toward a universal influenza vaccine</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400432</pub-id><?supplied-pmid 24994909?><pub-id pub-id-type="pmid">24994909</pub-id></element-citation></ref><ref id="B15-viruses-12-00276"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Holle</surname><given-names>T.A.</given-names></name><name><surname>Moody</surname><given-names>M.A.</given-names></name></person-group><article-title>Influenza and Antibody-Dependent Cellular Cytotoxicity</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1457</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01457</pub-id><?supplied-pmid 31316510?><pub-id pub-id-type="pmid">31316510</pub-id></element-citation></ref><ref id="B16-viruses-12-00276"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Weinfurter</surname><given-names>J.T.</given-names></name><name><surname>Friedrich</surname><given-names>T.C.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name></person-group><article-title>Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>5512</fpage><lpage>5522</lpage><pub-id pub-id-type="doi">10.1128/JVI.03030-12</pub-id><pub-id pub-id-type="pmid">23468501</pub-id></element-citation></ref><ref id="B17-viruses-12-00276"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asthagiri Arunkumar</surname><given-names>G.</given-names></name><name><surname>Ioannou</surname><given-names>A.</given-names></name><name><surname>Wohlbold</surname><given-names>T.J.</given-names></name><name><surname>Meade</surname><given-names>P.</given-names></name><name><surname>Aslam</surname><given-names>S.</given-names></name><name><surname>Amanat</surname><given-names>F.</given-names></name><name><surname>Ayllon</surname><given-names>J.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><pub-id pub-id-type="doi">10.1128/JVI.01696-18</pub-id></element-citation></ref><ref id="B18-viruses-12-00276"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry Dunand</surname><given-names>C.J.</given-names></name><name><surname>Leon</surname><given-names>P.E.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>A.</given-names></name><name><surname>Chromikova</surname><given-names>V.</given-names></name><name><surname>Ho</surname><given-names>I.Y.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Hirsh</surname><given-names>A.</given-names></name><name><surname>Zheng</surname><given-names>N.Y.</given-names></name><etal/></person-group><article-title>Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>800</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.05.014</pub-id><pub-id pub-id-type="pmid">27281570</pub-id></element-citation></ref><ref id="B19-viruses-12-00276"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padilla-Quirarte</surname><given-names>H.O.</given-names></name><name><surname>Lopez-Guerrero</surname><given-names>D.V.</given-names></name><name><surname>Gutierrez-Xicotencatl</surname><given-names>L.</given-names></name><name><surname>Esquivel-Guadarrama</surname><given-names>F.</given-names></name></person-group><article-title>Protective Antibodies Against Influenza Proteins</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1677</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01677</pub-id><pub-id pub-id-type="pmid">31379866</pub-id></element-citation></ref><ref id="B20-viruses-12-00276"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Luke</surname><given-names>C.</given-names></name><name><surname>Hickman</surname><given-names>H.D.</given-names></name><name><surname>Sangster</surname><given-names>M.Y.</given-names></name><name><surname>Wieland-Alter</surname><given-names>W.F.</given-names></name><name><surname>McBride</surname><given-names>J.M.</given-names></name><name><surname>Yewdell</surname><given-names>J.W.</given-names></name><name><surname>Wright</surname><given-names>P.F.</given-names></name><name><surname>Treanor</surname><given-names>J.</given-names></name><name><surname>Rosenberger</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>214</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw262</pub-id><pub-id pub-id-type="pmid">27354365</pub-id></element-citation></ref><ref id="B21-viruses-12-00276"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>R.D.</given-names></name><name><surname>Nieuwkoop</surname><given-names>N.J.</given-names></name><name><surname>Pronk</surname><given-names>M.</given-names></name><name><surname>de Bruin</surname><given-names>E.</given-names></name><name><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name><surname>Huijskens</surname><given-names>E.G.W.</given-names></name><name><surname>van Binnendijk</surname><given-names>R.S.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Koopmans</surname><given-names>M.P.G.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name></person-group><article-title>Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>238</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.082</pub-id><pub-id pub-id-type="pmid">27914742</pub-id></element-citation></ref><ref id="B22-viruses-12-00276"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>V.C.</given-names></name><name><surname>Lynch</surname><given-names>J.M.</given-names></name><name><surname>Bucher</surname><given-names>D.J.</given-names></name><name><surname>Le</surname><given-names>J.</given-names></name><name><surname>Metzger</surname><given-names>D.W.</given-names></name></person-group><article-title>Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections</article-title><source>J. Immunol.</source><year>2001</year><volume>166</volume><fpage>7381</fpage><lpage>7388</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.12.7381</pub-id><pub-id pub-id-type="pmid">11390489</pub-id></element-citation></ref><ref id="B23-viruses-12-00276"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Wilson</surname><given-names>J.R.</given-names></name><name><surname>Holiday</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Z.N.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Tzeng</surname><given-names>W.P.</given-names></name><name><surname>Stevens</surname><given-names>J.</given-names></name><name><surname>York</surname><given-names>I.A.</given-names></name><name><surname>Levine</surname><given-names>M.Z.</given-names></name></person-group><article-title>Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans</article-title><source>Open Forum Infect. Dis.</source><year>2016</year><volume>3</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofw102</pub-id><?supplied-pmid 27419174?><pub-id pub-id-type="pmid">27419174</pub-id></element-citation></ref><ref id="B24-viruses-12-00276"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>F.</given-names></name><name><surname>Shin</surname><given-names>H.S.</given-names></name><name><surname>Rhee</surname><given-names>S.G.</given-names></name></person-group><article-title>Tyrosine phosphorylation of phospholipase C-gamma 1 induced by cross-linking of the high-affinity or low-affinity Fc receptor for IgG in U937 cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1992</year><volume>89</volume><fpage>3659</fpage><lpage>3663</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.8.3659</pub-id><?supplied-pmid 1373507?><pub-id pub-id-type="pmid">1373507</pub-id></element-citation></ref><ref id="B25-viruses-12-00276"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Erbe</surname><given-names>A.K.</given-names></name><name><surname>Hank</surname><given-names>J.A.</given-names></name><name><surname>Morris</surname><given-names>Z.S.</given-names></name><name><surname>Sondel</surname><given-names>P.M.</given-names></name></person-group><article-title>NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy</article-title><source>Front. Immunol.</source><year>2015</year><volume>6</volume><fpage>368</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00368</pub-id><?supplied-pmid 26284063?><pub-id pub-id-type="pmid">26284063</pub-id></element-citation></ref><ref id="B26-viruses-12-00276"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimmerjahn</surname><given-names>F.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Fcgamma receptors as regulators of immune responses</article-title><source>Nat. Rev. Immunol.</source><year>2008</year><volume>8</volume><fpage>34</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nri2206</pub-id><pub-id pub-id-type="pmid">18064051</pub-id></element-citation></ref><ref id="B27-viruses-12-00276"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salk</surname><given-names>H.M.</given-names></name><name><surname>Haralambieva</surname><given-names>I.H.</given-names></name><name><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name><name><surname>Goergen</surname><given-names>K.M.</given-names></name><name><surname>Poland</surname><given-names>G.A.</given-names></name></person-group><article-title>Granzyme B ELISPOT assay to measure influenza-specific cellular immunity</article-title><source>J. Immunol. Methods</source><year>2013</year><volume>398</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2013.09.007</pub-id><pub-id pub-id-type="pmid">24055591</pub-id></element-citation></ref><ref id="B28-viruses-12-00276"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravetch</surname><given-names>J.V.</given-names></name><name><surname>Bolland</surname><given-names>S.</given-names></name></person-group><article-title>IgG Fc receptors</article-title><source>Annu. Rev. Immunol.</source><year>2001</year><volume>19</volume><fpage>275</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.275</pub-id><pub-id pub-id-type="pmid">11244038</pub-id></element-citation></ref><ref id="B29-viruses-12-00276"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiLillo</surname><given-names>D.J.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/nm.3443</pub-id><pub-id pub-id-type="pmid">24412922</pub-id></element-citation></ref><ref id="B30-viruses-12-00276"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>L.M.</given-names></name><name><surname>Surana</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Monoclonal antibodies: Versatile platforms for cancer immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>317</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nri2744</pub-id><pub-id pub-id-type="pmid">20414205</pub-id></element-citation></ref><ref id="B31-viruses-12-00276"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>H.W.</given-names><suffix>Jr.</suffix></name><name><surname>Cavacini</surname><given-names>L.</given-names></name></person-group><article-title>Structure and function of immunoglobulins</article-title><source>J. Allergy Clin. Immunol.</source><year>2010</year><volume>125</volume><fpage>S41</fpage><lpage>S52</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.046</pub-id><pub-id pub-id-type="pmid">20176268</pub-id></element-citation></ref><ref id="B32-viruses-12-00276"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>S.P.</given-names></name><name><surname>Finzi</surname><given-names>A.</given-names></name></person-group><article-title>Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><elocation-id>103</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7030103</pub-id></element-citation></ref><ref id="B33-viruses-12-00276"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruhns</surname><given-names>P.</given-names></name></person-group><article-title>Properties of mouse and human IgG receptors and their contribution to disease models</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>5640</fpage><lpage>5649</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-01-380121</pub-id><?supplied-pmid 22535666?><pub-id pub-id-type="pmid">22535666</pub-id></element-citation></ref><ref id="B34-viruses-12-00276"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravetch</surname><given-names>J.V.</given-names></name><name><surname>Kinet</surname><given-names>J.P.</given-names></name></person-group><article-title>Fc receptors</article-title><source>Annu. Rev. Immunol.</source><year>1991</year><volume>9</volume><fpage>457</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.09.040191.002325</pub-id><?supplied-pmid 1910686?><pub-id pub-id-type="pmid">1910686</pub-id></element-citation></ref><ref id="B35-viruses-12-00276"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimmerjahn</surname><given-names>F.</given-names></name><name><surname>Bruhns</surname><given-names>P.</given-names></name><name><surname>Horiuchi</surname><given-names>K.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>FcgammaRIV: A novel FcR with distinct IgG subclass specificity</article-title><source>Immunity</source><year>2005</year><volume>23</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.05.010</pub-id><?supplied-pmid 16039578?><pub-id pub-id-type="pmid">16039578</pub-id></element-citation></ref><ref id="B36-viruses-12-00276"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>P.</given-names></name><name><surname>DiLillo</surname><given-names>D.J.</given-names></name><name><surname>Bournazos</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Mouse model recapitulating human Fcgamma receptor structural and functional diversity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>6181</fpage><lpage>6186</lpage><pub-id pub-id-type="doi">10.1073/pnas.1203954109</pub-id><?supplied-pmid 22474370?><pub-id pub-id-type="pmid">22474370</pub-id></element-citation></ref><ref id="B37-viruses-12-00276"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irani</surname><given-names>V.</given-names></name><name><surname>Guy</surname><given-names>A.J.</given-names></name><name><surname>Andrew</surname><given-names>D.</given-names></name><name><surname>Beeson</surname><given-names>J.G.</given-names></name><name><surname>Ramsland</surname><given-names>P.A.</given-names></name><name><surname>Richards</surname><given-names>J.S.</given-names></name></person-group><article-title>Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases</article-title><source>Mol. Immunol.</source><year>2015</year><volume>67</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2015.03.255</pub-id><?supplied-pmid 25900877?><pub-id pub-id-type="pmid">25900877</pub-id></element-citation></ref><ref id="B38-viruses-12-00276"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Rivkin</surname><given-names>A.</given-names></name><name><surname>Pham</surname><given-names>T.</given-names></name></person-group><article-title>Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer</article-title><source>Clin. Ther.</source><year>2008</year><volume>30</volume><fpage>14</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2008.01.014</pub-id><pub-id pub-id-type="pmid">18343240</pub-id></element-citation></ref><ref id="B39-viruses-12-00276"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>The human antibody response to influenza A virus infection and vaccination</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>383</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0143-6</pub-id><pub-id pub-id-type="pmid">30837674</pub-id></element-citation></ref><ref id="B40-viruses-12-00276"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidarsson</surname><given-names>G.</given-names></name><name><surname>Dekkers</surname><given-names>G.</given-names></name><name><surname>Rispens</surname><given-names>T.</given-names></name></person-group><article-title>IgG subclasses and allotypes: From structure to effector functions</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>520</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00520</pub-id><pub-id pub-id-type="pmid">25368619</pub-id></element-citation></ref><ref id="B41-viruses-12-00276"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>Z.</given-names></name><name><surname>Forrest</surname><given-names>G.</given-names></name><name><surname>Moore</surname><given-names>R.</given-names></name><name><surname>Cukan</surname><given-names>M.</given-names></name><name><surname>Haytko</surname><given-names>P.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Vitelli</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>J.Z.</given-names></name><name><surname>Lu</surname><given-names>P.</given-names></name><name><surname>Hua</surname><given-names>J.</given-names></name><etal/></person-group><article-title>IgG2m4, an engineered antibody isotype with reduced Fc function</article-title><source>MAbs</source><year>2009</year><volume>1</volume><fpage>572</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.4161/mabs.1.6.10185</pub-id><pub-id pub-id-type="pmid">20073128</pub-id></element-citation></ref><ref id="B42-viruses-12-00276"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pincetic</surname><given-names>A.</given-names></name><name><surname>Bournazos</surname><given-names>S.</given-names></name><name><surname>DiLillo</surname><given-names>D.J.</given-names></name><name><surname>Maamary</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>T.T.</given-names></name><name><surname>Dahan</surname><given-names>R.</given-names></name><name><surname>Fiebiger</surname><given-names>B.M.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Type I and type II Fc receptors regulate innate and adaptive immunity</article-title><source>Nat. Immunol.</source><year>2014</year><volume>15</volume><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/ni.2939</pub-id><pub-id pub-id-type="pmid">25045879</pub-id></element-citation></ref><ref id="B43-viruses-12-00276"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondt</surname><given-names>A.</given-names></name><name><surname>Rombouts</surname><given-names>Y.</given-names></name><name><surname>Selman</surname><given-names>M.H.</given-names></name><name><surname>Hensbergen</surname><given-names>P.J.</given-names></name><name><surname>Reiding</surname><given-names>K.R.</given-names></name><name><surname>Hazes</surname><given-names>J.M.</given-names></name><name><surname>Dolhain</surname><given-names>R.J.</given-names></name><name><surname>Wuhrer</surname><given-names>M.</given-names></name></person-group><article-title>Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes</article-title><source>Mol. Cell Proteom.</source><year>2014</year><volume>13</volume><fpage>3029</fpage><lpage>3039</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.039537</pub-id><?supplied-pmid 25004930?><pub-id pub-id-type="pmid">25004930</pub-id></element-citation></ref><ref id="B44-viruses-12-00276"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>E.</given-names></name><name><surname>Tsukamoto</surname><given-names>Y.</given-names></name><name><surname>Sasaki</surname><given-names>R.</given-names></name><name><surname>Yagyu</surname><given-names>K.</given-names></name><name><surname>Takahashi</surname><given-names>N.</given-names></name></person-group><article-title>Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum</article-title><source>Glycoconj. J.</source><year>1997</year><volume>14</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1023/A:1018582930906</pub-id><?supplied-pmid 9147063?><pub-id pub-id-type="pmid">9147063</pub-id></element-citation></ref><ref id="B45-viruses-12-00276"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>J.S.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Kulhavy</surname><given-names>R.</given-names></name><name><surname>Tomana</surname><given-names>M.</given-names></name><name><surname>Novak</surname><given-names>J.</given-names></name><name><surname>Moldoveanu</surname><given-names>Z.</given-names></name><name><surname>Brown</surname><given-names>R.</given-names></name><name><surname>Goepfert</surname><given-names>P.A.</given-names></name><name><surname>Mestecky</surname><given-names>J.</given-names></name></person-group><article-title>Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals</article-title><source>AIDS</source><year>2005</year><volume>19</volume><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000161767.21405.68</pub-id><?supplied-pmid 15750391?><pub-id pub-id-type="pmid">15750391</pub-id></element-citation></ref><ref id="B46-viruses-12-00276"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinkawa</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Yamane</surname><given-names>N.</given-names></name><name><surname>Shoji-Hosaka</surname><given-names>E.</given-names></name><name><surname>Kanda</surname><given-names>Y.</given-names></name><name><surname>Sakurada</surname><given-names>M.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Anazawa</surname><given-names>H.</given-names></name><name><surname>Satoh</surname><given-names>M.</given-names></name><name><surname>Yamasaki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>3466</fpage><lpage>3473</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210665200</pub-id><pub-id pub-id-type="pmid">12427744</pub-id></element-citation></ref><ref id="B47-viruses-12-00276"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>C.</given-names></name><name><surname>Otte</surname><given-names>A.</given-names></name><name><surname>Cappuzzello</surname><given-names>E.</given-names></name><name><surname>Klausz</surname><given-names>K.</given-names></name><name><surname>Peipp</surname><given-names>M.</given-names></name></person-group><article-title>Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy</article-title><source>Transfus. Med. Hemother.</source><year>2017</year><volume>44</volume><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1159/000479980</pub-id><pub-id pub-id-type="pmid">29070978</pub-id></element-citation></ref><ref id="B48-viruses-12-00276"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnet</surname><given-names>C.</given-names></name><name><surname>Jorieux</surname><given-names>S.</given-names></name><name><surname>Souyris</surname><given-names>N.</given-names></name><name><surname>Zaki</surname><given-names>O.</given-names></name><name><surname>Jacquet</surname><given-names>A.</given-names></name><name><surname>Fournier</surname><given-names>N.</given-names></name><name><surname>Crozet</surname><given-names>F.</given-names></name><name><surname>de Romeuf</surname><given-names>C.</given-names></name><name><surname>Bouayadi</surname><given-names>K.</given-names></name><name><surname>Urbain</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody</article-title><source>MAbs</source><year>2014</year><volume>6</volume><fpage>422</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.4161/mabs.27854</pub-id><pub-id pub-id-type="pmid">24492301</pub-id></element-citation></ref><ref id="B49-viruses-12-00276"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Roman</surname><given-names>V.R.</given-names></name><name><surname>Florese</surname><given-names>R.H.</given-names></name><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Kalyanaraman</surname><given-names>V.S.</given-names></name><name><surname>Venzon</surname><given-names>D.</given-names></name><name><surname>Srivastava</surname><given-names>I.</given-names></name><name><surname>Barnett</surname><given-names>S.W.</given-names></name><name><surname>Robert-Guroff</surname><given-names>M.</given-names></name></person-group><article-title>An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2006</year><volume>43</volume><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1097/01.qai.0000230318.40170.60</pub-id><pub-id pub-id-type="pmid">16940858</pub-id></element-citation></ref><ref id="B50-viruses-12-00276"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>J.</given-names></name><name><surname>Prevost</surname><given-names>J.</given-names></name><name><surname>Alsahafi</surname><given-names>N.</given-names></name><name><surname>Ding</surname><given-names>S.</given-names></name><name><surname>Finzi</surname><given-names>A.</given-names></name></person-group><article-title>Impact of HIV-1 Envelope Conformation on ADCC Responses</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2017.10.007</pub-id><pub-id pub-id-type="pmid">29162391</pub-id></element-citation></ref><ref id="B51-viruses-12-00276"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saphire</surname><given-names>E.O.</given-names></name><name><surname>Schendel</surname><given-names>S.L.</given-names></name><name><surname>Fusco</surname><given-names>M.L.</given-names></name><name><surname>Gangavarapu</surname><given-names>K.</given-names></name><name><surname>Gunn</surname><given-names>B.M.</given-names></name><name><surname>Wec</surname><given-names>A.Z.</given-names></name><name><surname>Halfmann</surname><given-names>P.J.</given-names></name><name><surname>Brannan</surname><given-names>J.M.</given-names></name><name><surname>Herbert</surname><given-names>A.S.</given-names></name><name><surname>Qiu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection</article-title><source>Cell</source><year>2018</year><volume>174</volume><fpage>938</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.033</pub-id><pub-id pub-id-type="pmid">30096313</pub-id></element-citation></ref><ref id="B52-viruses-12-00276"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>G.</given-names></name><name><surname>Arango</surname><given-names>M.</given-names></name><name><surname>Perez</surname><given-names>A.B.</given-names></name><name><surname>Fonte</surname><given-names>L.</given-names></name><name><surname>Sierra</surname><given-names>B.</given-names></name><name><surname>Rodriguez-Roche</surname><given-names>R.</given-names></name><name><surname>Aguirre</surname><given-names>E.</given-names></name><name><surname>Fiterre</surname><given-names>I.</given-names></name><name><surname>Guzman</surname><given-names>M.G.</given-names></name></person-group><article-title>Antibodies from patients with dengue viral infection mediate cellular cytotoxicity</article-title><source>J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol.</source><year>2006</year><volume>37</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2006.04.010</pub-id></element-citation></ref><ref id="B53-viruses-12-00276"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Daniel</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Chancey</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Lei</surname><given-names>Y.F.</given-names></name><name><surname>Grinev</surname><given-names>A.</given-names></name><name><surname>Mostowski</surname><given-names>H.</given-names></name><name><surname>Rios</surname><given-names>M.</given-names></name><name><surname>Dayton</surname><given-names>A.</given-names></name></person-group><article-title>Anti-West Nile virus activity of in vitro expanded human primary natural killer cells</article-title><source>BMC Immunol.</source><year>2010</year><volume>11</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2172-11-3</pub-id><?supplied-pmid 20089143?><pub-id pub-id-type="pmid">20089143</pub-id></element-citation></ref><ref id="B54-viruses-12-00276"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rerks-Ngarm</surname><given-names>S.</given-names></name><name><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name><surname>Nitayaphan</surname><given-names>S.</given-names></name><name><surname>Kaewkungwal</surname><given-names>J.</given-names></name><name><surname>Chiu</surname><given-names>J.</given-names></name><name><surname>Paris</surname><given-names>R.</given-names></name><name><surname>Premsri</surname><given-names>N.</given-names></name><name><surname>Namwat</surname><given-names>C.</given-names></name><name><surname>de Souza</surname><given-names>M.</given-names></name><name><surname>Adams</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>2209</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908492</pub-id><?supplied-pmid 19843557?><pub-id pub-id-type="pmid">19843557</pub-id></element-citation></ref><ref id="B55-viruses-12-00276"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>D.C.</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>R.J.</given-names></name></person-group><article-title>Progress in HIV vaccine development</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>1018</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1276138</pub-id></element-citation></ref><ref id="B56-viruses-12-00276"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W.S.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name></person-group><article-title>Anti-HIV-1 antibody-dependent cellular cytotoxicity: Is there more to antibodies than neutralization?</article-title><source>Curr. Opin. HIV AIDS</source><year>2018</year><volume>13</volume><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000439</pub-id><pub-id pub-id-type="pmid">29194123</pub-id></element-citation></ref><ref id="B57-viruses-12-00276"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruel</surname><given-names>T.</given-names></name><name><surname>Guivel-Benhassine</surname><given-names>F.</given-names></name><name><surname>Lorin</surname><given-names>V.</given-names></name><name><surname>Lortat-Jacob</surname><given-names>H.</given-names></name><name><surname>Baleux</surname><given-names>F.</given-names></name><name><surname>Bourdic</surname><given-names>K.</given-names></name><name><surname>Noel</surname><given-names>N.</given-names></name><name><surname>Lambotte</surname><given-names>O.</given-names></name><name><surname>Mouquet</surname><given-names>H.</given-names></name><name><surname>Schwartz</surname><given-names>O.</given-names></name></person-group><article-title>Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><pub-id pub-id-type="doi">10.1128/JVI.02440-16</pub-id></element-citation></ref><ref id="B58-viruses-12-00276"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>A.W.</given-names></name><name><surname>Ghebremichael</surname><given-names>M.</given-names></name><name><surname>Robinson</surname><given-names>H.</given-names></name><name><surname>Brown</surname><given-names>E.</given-names></name><name><surname>Choi</surname><given-names>I.</given-names></name><name><surname>Lane</surname><given-names>S.</given-names></name><name><surname>Dugast</surname><given-names>A.S.</given-names></name><name><surname>Schoen</surname><given-names>M.K.</given-names></name><name><surname>Rolland</surname><given-names>M.</given-names></name><name><surname>Suscovich</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines</article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>228</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3007736</pub-id><?supplied-pmid 24648341?><pub-id pub-id-type="pmid">24648341</pub-id></element-citation></ref><ref id="B59-viruses-12-00276"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasekaran</surname><given-names>N.</given-names></name><name><surname>Chester</surname><given-names>C.</given-names></name><name><surname>Yonezawa</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Kohrt</surname><given-names>H.E.</given-names></name></person-group><article-title>Enhancement of antibody-dependent cell mediated cytotoxicity: A new era in cancer treatment</article-title><source>Immuno Targets Ther.</source><year>2015</year><volume>4</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.2147/ITT.S61292</pub-id></element-citation></ref><ref id="B60-viruses-12-00276"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramski</surname><given-names>M.</given-names></name><name><surname>Schorcht</surname><given-names>A.</given-names></name><name><surname>Johnston</surname><given-names>A.P.</given-names></name><name><surname>Lichtfuss</surname><given-names>G.F.</given-names></name><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>De Rose</surname><given-names>R.</given-names></name><name><surname>Stratov</surname><given-names>I.</given-names></name><name><surname>Kelleher</surname><given-names>A.D.</given-names></name><name><surname>French</surname><given-names>M.A.</given-names></name><name><surname>Center</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity</article-title><source>J. Immunol. Methods</source><year>2012</year><volume>384</volume><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2012.07.006</pub-id><?supplied-pmid 22841577?><pub-id pub-id-type="pmid">22841577</pub-id></element-citation></ref><ref id="B61-viruses-12-00276"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullarkey</surname><given-names>C.E.</given-names></name><name><surname>Bailey</surname><given-names>M.J.</given-names></name><name><surname>Golubeva</surname><given-names>D.A.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Novakowski</surname><given-names>K.E.</given-names></name><name><surname>Bowdish</surname><given-names>D.M.</given-names></name><name><surname>Miller</surname><given-names>M.S.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner</article-title><source>MBio</source><year>2016</year><volume>7</volume><pub-id pub-id-type="doi">10.1128/mBio.01624-16</pub-id></element-citation></ref><ref id="B62-viruses-12-00276"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>E.</given-names></name><name><surname>Reisfeld</surname><given-names>R.A.</given-names></name></person-group><article-title>A mechanism for neutrophil-mediated lysis of human neuroblastoma cells</article-title><source>Cancer Res.</source><year>1993</year><volume>53</volume><fpage>362</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">8417829</pub-id></element-citation></ref><ref id="B63-viruses-12-00276"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackerman</surname><given-names>M.E.</given-names></name><name><surname>Moldt</surname><given-names>B.</given-names></name><name><surname>Wyatt</surname><given-names>R.T.</given-names></name><name><surname>Dugast</surname><given-names>A.S.</given-names></name><name><surname>McAndrew</surname><given-names>E.</given-names></name><name><surname>Tsoukas</surname><given-names>S.</given-names></name><name><surname>Jost</surname><given-names>S.</given-names></name><name><surname>Berger</surname><given-names>C.T.</given-names></name><name><surname>Sciaranghella</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples</article-title><source>J. Immunol. Methods</source><year>2011</year><volume>366</volume><fpage>8</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2010.12.016</pub-id><?supplied-pmid 21192942?><pub-id pub-id-type="pmid">21192942</pub-id></element-citation></ref><ref id="B64-viruses-12-00276"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horner</surname><given-names>H.</given-names></name><name><surname>Frank</surname><given-names>C.</given-names></name><name><surname>Dechant</surname><given-names>C.</given-names></name><name><surname>Repp</surname><given-names>R.</given-names></name><name><surname>Glennie</surname><given-names>M.</given-names></name><name><surname>Herrmann</surname><given-names>M.</given-names></name><name><surname>Stockmeyer</surname><given-names>B.</given-names></name></person-group><article-title>Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity</article-title><source>J. Immunol.</source><year>2007</year><volume>179</volume><fpage>337</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.1.337</pub-id><?supplied-pmid 17579054?><pub-id pub-id-type="pmid">17579054</pub-id></element-citation></ref><ref id="B65-viruses-12-00276"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>E.</given-names></name></person-group><article-title>Contact-Induced Cytotoxicity by Lymphoid Cells Containing Foreign Isoantigens</article-title><source>Science</source><year>1965</year><volume>147</volume><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1126/science.147.3660.873</pub-id><?supplied-pmid 14245768?><pub-id pub-id-type="pmid">14245768</pub-id></element-citation></ref><ref id="B66-viruses-12-00276"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>G.K.</given-names></name><name><surname>Ackerman</surname><given-names>M.E.</given-names></name><name><surname>Scarlatti</surname><given-names>G.</given-names></name><name><surname>Moog</surname><given-names>C.</given-names></name><name><surname>Robert-Guroff</surname><given-names>M.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><name><surname>Overbaugh</surname><given-names>J.</given-names></name><name><surname>Reeves</surname><given-names>R.K.</given-names></name><name><surname>Ferrari</surname><given-names>G.</given-names></name><name><surname>Thyagarajan</surname><given-names>B.</given-names></name></person-group><article-title>Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1025</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01025</pub-id><pub-id pub-id-type="pmid">31134085</pub-id></element-citation></ref><ref id="B67-viruses-12-00276"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyler</surname><given-names>D.S.</given-names></name><name><surname>Stanley</surname><given-names>S.D.</given-names></name><name><surname>Nastala</surname><given-names>C.A.</given-names></name><name><surname>Austin</surname><given-names>A.A.</given-names></name><name><surname>Bartlett</surname><given-names>J.A.</given-names></name><name><surname>Stine</surname><given-names>K.C.</given-names></name><name><surname>Lyerly</surname><given-names>H.K.</given-names></name><name><surname>Bolognesi</surname><given-names>D.P.</given-names></name><name><surname>Weinhold</surname><given-names>K.J.</given-names></name></person-group><article-title>Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects</article-title><source>J. Immunol.</source><year>1990</year><volume>144</volume><fpage>3375</fpage><lpage>3384</lpage><pub-id pub-id-type="pmid">2329275</pub-id></element-citation></ref><ref id="B68-viruses-12-00276"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>L.L.</given-names></name><name><surname>Cassutt</surname><given-names>K.J.</given-names></name><name><surname>Knigge</surname><given-names>K.</given-names></name><name><surname>Khattri</surname><given-names>R.</given-names></name><name><surname>Margolick</surname><given-names>J.</given-names></name><name><surname>Rinaldo</surname><given-names>C.</given-names></name><name><surname>Kleeberger</surname><given-names>C.A.</given-names></name><name><surname>Nishanian</surname><given-names>P.</given-names></name><name><surname>Henrard</surname><given-names>D.R.</given-names></name><name><surname>Phair</surname><given-names>J.</given-names></name></person-group><article-title>HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression</article-title><source>J. Immunol.</source><year>1996</year><volume>157</volume><fpage>2168</fpage><lpage>2173</lpage><pub-id pub-id-type="pmid">8757343</pub-id></element-citation></ref><ref id="B69-viruses-12-00276"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurane</surname><given-names>I.</given-names></name><name><surname>Hebblewaite</surname><given-names>D.</given-names></name><name><surname>Brandt</surname><given-names>W.E.</given-names></name><name><surname>Ennis</surname><given-names>F.A.</given-names></name></person-group><article-title>Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity</article-title><source>J. Virol.</source><year>1984</year><volume>52</volume><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1128/JVI.52.1.223-230.1984</pub-id><pub-id pub-id-type="pmid">6207308</pub-id></element-citation></ref><ref id="B70-viruses-12-00276"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>V.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>M.Y.</given-names></name></person-group><article-title>Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>5831</fpage><lpage>5840</lpage><pub-id pub-id-type="doi">10.1128/JVI.00273-13</pub-id><pub-id pub-id-type="pmid">23487456</pub-id></element-citation></ref><ref id="B71-viruses-12-00276"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Z.W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Poon</surname><given-names>K.M.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Shuai</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the Hemagglutinin Head Region of Pandemic H1N1 Influenza Virus Play Detrimental Roles in H1N1-Infected Mice</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>317</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00317</pub-id><pub-id pub-id-type="pmid">28377769</pub-id></element-citation></ref><ref id="B72-viruses-12-00276"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radosevic</surname><given-names>K.</given-names></name><name><surname>Garritsen</surname><given-names>H.S.</given-names></name><name><surname>Van Graft</surname><given-names>M.</given-names></name><name><surname>De Grooth</surname><given-names>B.G.</given-names></name><name><surname>Greve</surname><given-names>J.</given-names></name></person-group><article-title>A simple and sensitive flow cytometric assay for the determination of the cytotoxic activity of human natural killer cells</article-title><source>J. Immunol. Methods</source><year>1990</year><volume>135</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(90)90259-X</pub-id><pub-id pub-id-type="pmid">2273268</pub-id></element-citation></ref><ref id="B73-viruses-12-00276"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>R.D.</given-names></name><name><surname>Nieuwkoop</surname><given-names>N.J.</given-names></name><name><surname>van der Klis</surname><given-names>F.R.M.</given-names></name><name><surname>Koopmans</surname><given-names>M.P.G.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name></person-group><article-title>Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>217</volume><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix546</pub-id><pub-id pub-id-type="pmid">29294018</pub-id></element-citation></ref><ref id="B74-viruses-12-00276"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>N.</given-names></name><name><surname>Swem</surname><given-names>L.R.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Nakamura</surname><given-names>G.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Estevez</surname><given-names>A.</given-names></name><name><surname>Fong</surname><given-names>R.</given-names></name><name><surname>Kamen</surname><given-names>L.</given-names></name><name><surname>Kho</surname><given-names>E.</given-names></name><name><surname>Reichelt</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>14234</fpage><pub-id pub-id-type="doi">10.1038/ncomms14234</pub-id><pub-id pub-id-type="pmid">28102191</pub-id></element-citation></ref><ref id="B75-viruses-12-00276"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>G.</given-names></name><name><surname>Malenfant</surname><given-names>J.M.</given-names></name><name><surname>Altfeld</surname><given-names>M.</given-names></name></person-group><article-title>CD107a as a functional marker for the identification of natural killer cell activity</article-title><source>J. Immunol. Methods</source><year>2004</year><volume>294</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2004.08.008</pub-id><?supplied-pmid 15604012?><pub-id pub-id-type="pmid">15604012</pub-id></element-citation></ref><ref id="B76-viruses-12-00276"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krzewski</surname><given-names>K.</given-names></name><name><surname>Gil-Krzewska</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>V.</given-names></name><name><surname>Peruzzi</surname><given-names>G.</given-names></name><name><surname>Coligan</surname><given-names>J.E.</given-names></name></person-group><article-title>LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>4672</fpage><lpage>4683</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-08-453738</pub-id><?supplied-pmid 23632890?><pub-id pub-id-type="pmid">23632890</pub-id></element-citation></ref><ref id="B77-viruses-12-00276"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>A.W.</given-names></name><name><surname>Navis</surname><given-names>M.</given-names></name><name><surname>Isitman</surname><given-names>G.</given-names></name><name><surname>Wren</surname><given-names>L.</given-names></name><name><surname>Silvers</surname><given-names>J.</given-names></name><name><surname>Amin</surname><given-names>J.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><name><surname>Stratov</surname><given-names>I.</given-names></name></person-group><article-title>Activation of NK cells by ADCC antibodies and HIV disease progression</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2011</year><volume>58</volume><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e31822c62b9</pub-id><?supplied-pmid 21792067?><pub-id pub-id-type="pmid">21792067</pub-id></element-citation></ref><ref id="B78-viruses-12-00276"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madhavi</surname><given-names>V.</given-names></name><name><surname>Navis</surname><given-names>M.</given-names></name><name><surname>Chung</surname><given-names>A.W.</given-names></name><name><surname>Isitman</surname><given-names>G.</given-names></name><name><surname>Wren</surname><given-names>L.H.</given-names></name><name><surname>De Rose</surname><given-names>R.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><name><surname>Stratov</surname><given-names>I.</given-names></name></person-group><article-title>Activation of NK cells by HIV-specific ADCC antibodies: Role for granulocytes in expressing HIV-1 peptide epitopes</article-title><source>Hum. Vaccines Immunother.</source><year>2013</year><volume>9</volume><fpage>1011</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.4161/hv.23446</pub-id><?supplied-pmid 23324623?><pub-id pub-id-type="pmid">23324623</pub-id></element-citation></ref><ref id="B79-viruses-12-00276"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z.J.</given-names></name><name><surname>Garvin</surname><given-names>D.</given-names></name><name><surname>Paguio</surname><given-names>A.</given-names></name><name><surname>Moravec</surname><given-names>R.</given-names></name><name><surname>Engel</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>F.</given-names></name><name><surname>Surowy</surname><given-names>T.</given-names></name></person-group><article-title>Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies</article-title><source>J. Immunol. Methods</source><year>2014</year><volume>414</volume><fpage>69</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2014.07.010</pub-id><pub-id pub-id-type="pmid">25086226</pub-id></element-citation></ref><ref id="B80-viruses-12-00276"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Leon</surname><given-names>P.E.</given-names></name><name><surname>Albrecht</surname><given-names>R.A.</given-names></name><name><surname>Margine</surname><given-names>I.</given-names></name><name><surname>Hirsh</surname><given-names>A.</given-names></name><name><surname>Bahl</surname><given-names>J.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005578</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005578</pub-id><pub-id pub-id-type="pmid">27081859</pub-id></element-citation></ref><ref id="B81-viruses-12-00276"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F.</given-names></name><name><surname>Meade</surname><given-names>P.</given-names></name><name><surname>Strohmeier</surname><given-names>S.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model</article-title><source>Emerg. Microbes Infect.</source><year>2019</year><volume>8</volume><fpage>155</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1080/22221751.2018.1564369</pub-id><pub-id pub-id-type="pmid">30866770</pub-id></element-citation></ref><ref id="B82-viruses-12-00276"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>F.</given-names></name><name><surname>Kwaks</surname><given-names>T.</given-names></name><name><surname>Brandenburg</surname><given-names>B.</given-names></name><name><surname>Koldijk</surname><given-names>M.H.</given-names></name><name><surname>Klaren</surname><given-names>V.</given-names></name><name><surname>Smal</surname><given-names>B.</given-names></name><name><surname>Korse</surname><given-names>H.J.</given-names></name><name><surname>Geelen</surname><given-names>E.</given-names></name><name><surname>Tettero</surname><given-names>L.</given-names></name><name><surname>Zuijdgeest</surname><given-names>D.</given-names></name><etal/></person-group><article-title>HA Antibody-Mediated FcgammaRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>399</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00399</pub-id><pub-id pub-id-type="pmid">27746785</pub-id></element-citation></ref><ref id="B83-viruses-12-00276"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Mullarkey</surname><given-names>C.E.</given-names></name><name><surname>Lee</surname><given-names>A.J.</given-names></name><name><surname>Lam</surname><given-names>M.M.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Henry</surname><given-names>C.</given-names></name><name><surname>Wilson</surname><given-names>P.C.</given-names></name><name><surname>Ashkar</surname><given-names>A.A.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>11931</fpage><lpage>11936</lpage><pub-id pub-id-type="doi">10.1073/pnas.1609316113</pub-id><?supplied-pmid 27698132?><pub-id pub-id-type="pmid">27698132</pub-id></element-citation></ref><ref id="B84-viruses-12-00276"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ermler</surname><given-names>M.E.</given-names></name><name><surname>Kirkpatrick</surname><given-names>E.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Hai</surname><given-names>R.</given-names></name><name><surname>Amanat</surname><given-names>F.</given-names></name><name><surname>Chromikova</surname><given-names>V.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><pub-id pub-id-type="doi">10.1128/JVI.00286-17</pub-id><?supplied-pmid 28356526?><pub-id pub-id-type="pmid">28356526</pub-id></element-citation></ref><ref id="B85-viruses-12-00276"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S.F.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Kaur</surname><given-names>K.</given-names></name><name><surname>Popova</surname><given-names>L.I.</given-names></name><name><surname>Ho</surname><given-names>I.Y.</given-names></name><name><surname>Pauli</surname><given-names>N.T.</given-names></name><name><surname>Henry Dunand</surname><given-names>C.J.</given-names></name><name><surname>Taylor</surname><given-names>W.M.</given-names></name><name><surname>Lim</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Immune history profoundly affects broadly protective B cell responses to influenza</article-title><source>Sci. Transl. Med.</source><year>2015</year><volume>7</volume><fpage>316ra192</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aad0522</pub-id><?supplied-pmid 26631631?><pub-id pub-id-type="pmid">26631631</pub-id></element-citation></ref><ref id="B86-viruses-12-00276"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Influenza virus hemagglutinin stalk-based antibodies and vaccines</article-title><source>Curr. Opin. Virol.</source><year>2013</year><volume>3</volume><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2013.07.007</pub-id><pub-id pub-id-type="pmid">23978327</pub-id></element-citation></ref><ref id="B87-viruses-12-00276"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Eggink</surname><given-names>D.</given-names></name><name><surname>Kongchanagul</surname><given-names>A.</given-names></name><name><surname>Moran</surname><given-names>T.M.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>6179</fpage><lpage>6188</lpage><pub-id pub-id-type="doi">10.1128/JVI.00469-12</pub-id><pub-id pub-id-type="pmid">22491456</pub-id></element-citation></ref><ref id="B88-viruses-12-00276"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desbien</surname><given-names>A.L.</given-names></name><name><surname>Van Hoeven</surname><given-names>N.</given-names></name><name><surname>Reed</surname><given-names>S.J.</given-names></name><name><surname>Casey</surname><given-names>A.C.</given-names></name><name><surname>Laurance</surname><given-names>J.D.</given-names></name><name><surname>Baldwin</surname><given-names>S.L.</given-names></name><name><surname>Duthie</surname><given-names>M.S.</given-names></name><name><surname>Reed</surname><given-names>S.G.</given-names></name><name><surname>Carter</surname><given-names>D.</given-names></name></person-group><article-title>Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses</article-title><source>Biotechniques</source><year>2013</year><volume>54</volume><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.2144/000114041</pub-id><pub-id pub-id-type="pmid">23750544</pub-id></element-citation></ref><ref id="B89-viruses-12-00276"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreyfus</surname><given-names>C.</given-names></name><name><surname>Laursen</surname><given-names>N.S.</given-names></name><name><surname>Kwaks</surname><given-names>T.</given-names></name><name><surname>Zuijdgeest</surname><given-names>D.</given-names></name><name><surname>Khayat</surname><given-names>R.</given-names></name><name><surname>Ekiert</surname><given-names>D.C.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Metlagel</surname><given-names>Z.</given-names></name><name><surname>Bujny</surname><given-names>M.V.</given-names></name><name><surname>Jongeneelen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Highly conserved protective epitopes on influenza B viruses</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>1343</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1126/science.1222908</pub-id><pub-id pub-id-type="pmid">22878502</pub-id></element-citation></ref><ref id="B90-viruses-12-00276"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>D.C.</given-names></name><name><surname>Friesen</surname><given-names>R.H.</given-names></name><name><surname>Bhabha</surname><given-names>G.</given-names></name><name><surname>Kwaks</surname><given-names>T.</given-names></name><name><surname>Jongeneelen</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Ophorst</surname><given-names>C.</given-names></name><name><surname>Cox</surname><given-names>F.</given-names></name><name><surname>Korse</surname><given-names>H.J.</given-names></name><name><surname>Brandenburg</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A highly conserved neutralizing epitope on group 2 influenza A viruses</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1126/science.1204839</pub-id><pub-id pub-id-type="pmid">21737702</pub-id></element-citation></ref><ref id="B91-viruses-12-00276"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.T.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Hai</surname><given-names>R.</given-names></name><name><surname>Pica</surname><given-names>N.</given-names></name><name><surname>Petersen</surname><given-names>E.</given-names></name><name><surname>Moran</surname><given-names>T.M.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><elocation-id>e1000796</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000796</pub-id><pub-id pub-id-type="pmid">20195520</pub-id></element-citation></ref><ref id="B92-viruses-12-00276"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasugi</surname><given-names>M.</given-names></name><name><surname>Kubota-Koketsu</surname><given-names>R.</given-names></name><name><surname>Yamashita</surname><given-names>A.</given-names></name><name><surname>Kawashita</surname><given-names>N.</given-names></name><name><surname>Du</surname><given-names>A.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Nishimura</surname><given-names>M.</given-names></name><name><surname>Misaki</surname><given-names>R.</given-names></name><name><surname>Kuhara</surname><given-names>M.</given-names></name><name><surname>Boonsathorn</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Human monoclonal antibodies broadly neutralizing against influenza B virus</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003150</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003150</pub-id><pub-id pub-id-type="pmid">23408886</pub-id></element-citation></ref><ref id="B93-viruses-12-00276"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>N.C.</given-names></name><name><surname>Lerner</surname><given-names>R.A.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem</article-title><source>Cell Rep.</source><year>2017</year><volume>20</volume><fpage>2935</fpage><lpage>2943</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.08.084</pub-id><?supplied-pmid 28930686?><pub-id pub-id-type="pmid">28930686</pub-id></element-citation></ref><ref id="B94-viruses-12-00276"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Voss</surname><given-names>J.</given-names></name><name><surname>Gamblin</surname><given-names>S.J.</given-names></name><name><surname>Codoni</surname><given-names>G.</given-names></name><name><surname>Macagno</surname><given-names>A.</given-names></name><name><surname>Jarrossay</surname><given-names>D.</given-names></name><name><surname>Vachieri</surname><given-names>S.G.</given-names></name><name><surname>Pinna</surname><given-names>D.</given-names></name><name><surname>Minola</surname><given-names>A.</given-names></name><name><surname>Vanzetta</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>850</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1126/science.1205669</pub-id><?supplied-pmid 21798894?><pub-id pub-id-type="pmid">21798894</pub-id></element-citation></ref><ref id="B95-viruses-12-00276"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>D.C.</given-names></name><name><surname>Bhabha</surname><given-names>G.</given-names></name><name><surname>Elsliger</surname><given-names>M.A.</given-names></name><name><surname>Friesen</surname><given-names>R.H.</given-names></name><name><surname>Jongeneelen</surname><given-names>M.</given-names></name><name><surname>Throsby</surname><given-names>M.</given-names></name><name><surname>Goudsmit</surname><given-names>J.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Antibody recognition of a highly conserved influenza virus epitope</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1126/science.1171491</pub-id><?supplied-pmid 19251591?><pub-id pub-id-type="pmid">19251591</pub-id></element-citation></ref><ref id="B96-viruses-12-00276"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laursen</surname><given-names>N.S.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Broadly neutralizing antibodies against influenza viruses</article-title><source>Antivir. Res.</source><year>2013</year><volume>98</volume><fpage>476</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.03.021</pub-id><pub-id pub-id-type="pmid">23583287</pub-id></element-citation></ref><ref id="B97-viruses-12-00276"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Novel universal influenza virus vaccine approaches</article-title><source>Curr. Opin. Virol.</source><year>2016</year><volume>17</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2016.02.002</pub-id><pub-id pub-id-type="pmid">26927813</pub-id></element-citation></ref><ref id="B98-viruses-12-00276"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>Kinzler</surname><given-names>D.</given-names></name><name><surname>Choi</surname><given-names>A.</given-names></name><name><surname>Hirsh</surname><given-names>A.</given-names></name><name><surname>Beaulieu</surname><given-names>E.</given-names></name><name><surname>Lecrenier</surname><given-names>N.</given-names></name><name><surname>Innis</surname><given-names>B.L.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Mallett</surname><given-names>C.P.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice</article-title><source>NPJ Vaccines</source><year>2016</year><volume>1</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/npjvaccines.2016.15</pub-id></element-citation></ref><ref id="B99-viruses-12-00276"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Universal influenza virus vaccines and therapeutic antibodies</article-title><source>Clin. Microbiol. Infect.</source><year>2017</year><volume>23</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2017.02.009</pub-id><pub-id pub-id-type="pmid">28216325</pub-id></element-citation></ref><ref id="B100-viruses-12-00276"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiLillo</surname><given-names>D.J.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Wilson</surname><given-names>P.C.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection</article-title><source>J. Clin. Investig.</source><year>2016</year><volume>126</volume><fpage>605</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1172/JCI84428</pub-id><pub-id pub-id-type="pmid">26731473</pub-id></element-citation></ref><ref id="B101-viruses-12-00276"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandenburg</surname><given-names>B.</given-names></name><name><surname>Koudstaal</surname><given-names>W.</given-names></name><name><surname>Goudsmit</surname><given-names>J.</given-names></name><name><surname>Klaren</surname><given-names>V.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name><name><surname>Bujny</surname><given-names>M.V.</given-names></name><name><surname>Korse</surname><given-names>H.J.</given-names></name><name><surname>Kwaks</surname><given-names>T.</given-names></name><name><surname>Otterstrom</surname><given-names>J.J.</given-names></name><name><surname>Juraszek</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Mechanisms of hemagglutinin targeted influenza virus neutralization</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e80034</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0080034</pub-id><pub-id pub-id-type="pmid">24348996</pub-id></element-citation></ref><ref id="B102-viruses-12-00276"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangaru</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Gilchuk</surname><given-names>I.M.</given-names></name><name><surname>Voss</surname><given-names>T.G.</given-names></name><name><surname>Irving</surname><given-names>R.P.</given-names></name><name><surname>Gilchuk</surname><given-names>P.</given-names></name><name><surname>Matta</surname><given-names>P.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Lang</surname><given-names>S.</given-names></name><name><surname>Nieusma</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2669</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04704-9</pub-id><pub-id pub-id-type="pmid">29991715</pub-id></element-citation></ref><ref id="B103-viruses-12-00276"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>A.</given-names></name><name><surname>McCarthy</surname><given-names>K.R.</given-names></name><name><surname>Kuraoka</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>A.G.</given-names></name><name><surname>Adachi</surname><given-names>Y.</given-names></name><name><surname>Onodera</surname><given-names>T.</given-names></name><name><surname>Tonouchi</surname><given-names>K.</given-names></name><name><surname>Caradonna</surname><given-names>T.M.</given-names></name><name><surname>Bajic</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1124</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.03.048</pub-id><pub-id pub-id-type="pmid">31100267</pub-id></element-citation></ref><ref id="B104-viruses-12-00276"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangaru</surname><given-names>S.</given-names></name><name><surname>Lang</surname><given-names>S.</given-names></name><name><surname>Schotsaert</surname><given-names>M.</given-names></name><name><surname>Vanderven</surname><given-names>H.A.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Kose</surname><given-names>N.</given-names></name><name><surname>Bombardi</surname><given-names>R.</given-names></name><name><surname>Finn</surname><given-names>J.A.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><name><surname>Gilchuk</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1136</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.011</pub-id><?supplied-pmid 31100268?><pub-id pub-id-type="pmid">31100268</pub-id></element-citation></ref><ref id="B105-viruses-12-00276"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>P.E.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Mullarkey</surname><given-names>C.E.</given-names></name><name><surname>Bailey</surname><given-names>M.J.</given-names></name><name><surname>Miller</surname><given-names>M.S.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name></person-group><article-title>Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E5944</fpage><lpage>E5951</lpage><pub-id pub-id-type="doi">10.1073/pnas.1613225113</pub-id><?supplied-pmid 27647907?><pub-id pub-id-type="pmid">27647907</pub-id></element-citation></ref><ref id="B106-viruses-12-00276"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Stegalkina</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Bi</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses</article-title><source>Sci. Transl. Med.</source><year>2017</year><volume>9</volume><pub-id pub-id-type="doi">10.1126/scitranslmed.aam5752</pub-id><?supplied-pmid 29046433?><pub-id pub-id-type="pmid">29046433</pub-id></element-citation></ref><ref id="B107-viruses-12-00276"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>A.</given-names></name><name><surname>Pleschka</surname><given-names>S.</given-names></name></person-group><article-title>Influenza H3N2 Vaccines: Recent Challenges</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>87</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2017.12.003</pub-id><?supplied-pmid 29268980?><pub-id pub-id-type="pmid">29268980</pub-id></element-citation></ref><ref id="B108-viruses-12-00276"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neirynck</surname><given-names>S.</given-names></name><name><surname>Deroo</surname><given-names>T.</given-names></name><name><surname>Saelens</surname><given-names>X.</given-names></name><name><surname>Vanlandschoot</surname><given-names>P.</given-names></name><name><surname>Jou</surname><given-names>W.M.</given-names></name><name><surname>Fiers</surname><given-names>W.</given-names></name></person-group><article-title>A universal influenza A vaccine based on the extracellular domain of the M2 protein</article-title><source>Nat. Med.</source><year>1999</year><volume>5</volume><fpage>1157</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1038/13484</pub-id><pub-id pub-id-type="pmid">10502819</pub-id></element-citation></ref><ref id="B109-viruses-12-00276"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schotsaert</surname><given-names>M.</given-names></name><name><surname>De Filette</surname><given-names>M.</given-names></name><name><surname>Fiers</surname><given-names>W.</given-names></name><name><surname>Saelens</surname><given-names>X.</given-names></name></person-group><article-title>Universal M2 ectodomain-based influenza A vaccines: Preclinical and clinical developments</article-title><source>Expert Rev. Vaccines</source><year>2009</year><volume>8</volume><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1586/erv.09.6</pub-id><pub-id pub-id-type="pmid">19348565</pub-id></element-citation></ref><ref id="B110-viruses-12-00276"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichelberger</surname><given-names>M.C.</given-names></name><name><surname>Monto</surname><given-names>A.S.</given-names></name></person-group><article-title>Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>219</volume><fpage>S75</fpage><lpage>S80</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz017</pub-id><pub-id pub-id-type="pmid">30715357</pub-id></element-citation></ref><ref id="B111-viruses-12-00276"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlbold</surname><given-names>T.J.</given-names></name><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Hirsh</surname><given-names>A.</given-names></name><name><surname>Brokstad</surname><given-names>K.A.</given-names></name><name><surname>Cox</surname><given-names>R.J.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice</article-title><source>MBio</source><year>2015</year><volume>6</volume><fpage>e02556</fpage><pub-id pub-id-type="doi">10.1128/mBio.02556-14</pub-id><pub-id pub-id-type="pmid">25759506</pub-id></element-citation></ref><ref id="B112-viruses-12-00276"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlbold</surname><given-names>T.J.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>In the shadow of hemagglutinin: A growing interest in influenza viral neuraminidase and its role as a vaccine antigen</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>2465</fpage><lpage>2494</lpage><pub-id pub-id-type="doi">10.3390/v6062465</pub-id><pub-id pub-id-type="pmid">24960271</pub-id></element-citation></ref><ref id="B113-viruses-12-00276"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadlbauer</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>McMahon</surname><given-names>M.</given-names></name><name><surname>Turner</surname><given-names>J.S.</given-names></name><name><surname>Wohlbold</surname><given-names>T.J.</given-names></name><name><surname>Schmitz</surname><given-names>A.J.</given-names></name><name><surname>Strohmeier</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>Mudd</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Broadly protective human antibodies that target the active site of influenza virus neuraminidase</article-title><source>Science</source><year>2019</year><volume>366</volume><fpage>499</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1126/science.aay0678</pub-id><?supplied-pmid 31649200?><pub-id pub-id-type="pmid">31649200</pub-id></element-citation></ref><ref id="B114-viruses-12-00276"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cady</surname><given-names>S.D.</given-names></name><name><surname>Luo</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Hong</surname><given-names>M.</given-names></name></person-group><article-title>Structure and function of the influenza A M2 proton channel</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>7356</fpage><lpage>7364</lpage><pub-id pub-id-type="doi">10.1021/bi9008837</pub-id><?supplied-pmid 19601584?><pub-id pub-id-type="pmid">19601584</pub-id></element-citation></ref><ref id="B115-viruses-12-00276"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pielak</surname><given-names>R.M.</given-names></name><name><surname>Chou</surname><given-names>J.J.</given-names></name></person-group><article-title>Influenza M2 proton channels</article-title><source>Biochim. Biophys. Acta</source><year>2011</year><volume>1808</volume><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2010.04.015</pub-id><?supplied-pmid 20451491?><pub-id pub-id-type="pmid">20451491</pub-id></element-citation></ref><ref id="B116-viruses-12-00276"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Y.H.</given-names></name></person-group><article-title>Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>3463</fpage><lpage>3469</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.03.021</pub-id><?supplied-pmid 22446634?><pub-id pub-id-type="pmid">22446634</pub-id></element-citation></ref><ref id="B117-viruses-12-00276"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Bakkouri</surname><given-names>K.</given-names></name><name><surname>Descamps</surname><given-names>F.</given-names></name><name><surname>De Filette</surname><given-names>M.</given-names></name><name><surname>Smet</surname><given-names>A.</given-names></name><name><surname>Festjens</surname><given-names>E.</given-names></name><name><surname>Birkett</surname><given-names>A.</given-names></name><name><surname>Van Rooijen</surname><given-names>N.</given-names></name><name><surname>Verbeek</surname><given-names>S.</given-names></name><name><surname>Fiers</surname><given-names>W.</given-names></name><name><surname>Saelens</surname><given-names>X.</given-names></name></person-group><article-title>Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection</article-title><source>J. Immunol.</source><year>2011</year><volume>186</volume><fpage>1022</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902147</pub-id><pub-id pub-id-type="pmid">21169548</pub-id></element-citation></ref><ref id="B118-viruses-12-00276"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Ko</surname><given-names>E.J.</given-names></name><name><surname>Lee</surname><given-names>Y.N.</given-names></name><name><surname>Kim</surname><given-names>M.C.</given-names></name><name><surname>Kwon</surname><given-names>Y.M.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Cho</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>Y.J.</given-names></name><name><surname>Kang</surname><given-names>S.M.</given-names></name></person-group><article-title>New vaccines against influenza virus</article-title><source>Clin. Exp. Vaccine Res.</source><year>2014</year><volume>3</volume><fpage>12</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.7774/cevr.2014.3.1.12</pub-id><pub-id pub-id-type="pmid">24427759</pub-id></element-citation></ref><ref id="B119-viruses-12-00276"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepens</surname><given-names>B.</given-names></name><name><surname>De Vlieger</surname><given-names>D.</given-names></name><name><surname>Saelens</surname><given-names>X.</given-names></name></person-group><article-title>Vaccine options for influenza: Thinking small</article-title><source>Curr. Opin. Immunol.</source><year>2018</year><volume>53</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2018.03.024</pub-id><pub-id pub-id-type="pmid">29631195</pub-id></element-citation></ref><ref id="B120-viruses-12-00276"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.N.</given-names></name><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Kim</surname><given-names>M.C.</given-names></name><name><surname>Hwang</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Kang</surname><given-names>S.M.</given-names></name></person-group><article-title>Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination</article-title><source>Immunology</source><year>2014</year><volume>143</volume><fpage>300</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1111/imm.12310</pub-id><pub-id pub-id-type="pmid">24773389</pub-id></element-citation></ref><ref id="B121-viruses-12-00276"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolpe</surname><given-names>A.</given-names></name><name><surname>Schepens</surname><given-names>B.</given-names></name><name><surname>Fiers</surname><given-names>W.</given-names></name><name><surname>Saelens</surname><given-names>X.</given-names></name></person-group><article-title>M2-based influenza vaccines: Recent advances and clinical potential</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>123</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1240041</pub-id><pub-id pub-id-type="pmid">27653543</pub-id></element-citation></ref><ref id="B122-viruses-12-00276"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>A.</given-names></name><name><surname>Myojo</surname><given-names>K.</given-names></name><name><surname>Laudenslager</surname><given-names>J.</given-names></name><name><surname>Harada</surname><given-names>D.</given-names></name><name><surname>Miura</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Kuni-Kamochi</surname><given-names>R.</given-names></name><name><surname>Soloff</surname><given-names>R.</given-names></name><name><surname>Ohgami</surname><given-names>K.</given-names></name><name><surname>Kanda</surname><given-names>Y.</given-names></name></person-group><article-title>Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates</article-title><source>Antivir. Res.</source><year>2014</year><volume>111</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.08.016</pub-id><pub-id pub-id-type="pmid">25218949</pub-id></element-citation></ref><ref id="B123-viruses-12-00276"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virelizier</surname><given-names>J.L.</given-names></name><name><surname>Allison</surname><given-names>A.C.</given-names></name><name><surname>Oxford</surname><given-names>J.S.</given-names></name><name><surname>Schild</surname><given-names>G.C.</given-names></name></person-group><article-title>Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells</article-title><source>Nature</source><year>1977</year><volume>266</volume><fpage>52</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/266052a0</pub-id><?supplied-pmid 840296?><pub-id pub-id-type="pmid">840296</pub-id></element-citation></ref><ref id="B124-viruses-12-00276"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yewdell</surname><given-names>J.W.</given-names></name><name><surname>Frank</surname><given-names>E.</given-names></name><name><surname>Gerhard</surname><given-names>W.</given-names></name></person-group><article-title>Expression of influenza A virus internal antigens on the surface of infected P815 cells</article-title><source>J. Immunol.</source><year>1981</year><volume>126</volume><fpage>1814</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">7217668</pub-id></element-citation></ref><ref id="B125-viruses-12-00276"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antrobus</surname><given-names>R.D.</given-names></name><name><surname>Lillie</surname><given-names>P.J.</given-names></name><name><surname>Berthoud</surname><given-names>T.K.</given-names></name><name><surname>Spencer</surname><given-names>A.J.</given-names></name><name><surname>McLaren</surname><given-names>J.E.</given-names></name><name><surname>Ladell</surname><given-names>K.</given-names></name><name><surname>Lambe</surname><given-names>T.</given-names></name><name><surname>Milicic</surname><given-names>A.</given-names></name><name><surname>Price</surname><given-names>D.A.</given-names></name><name><surname>Hill</surname><given-names>A.V.</given-names></name><etal/></person-group><article-title>A T cell-inducing influenza vaccine for the elderly: Safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e48322</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0048322</pub-id><pub-id pub-id-type="pmid">23118984</pub-id></element-citation></ref><ref id="B126-viruses-12-00276"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Development of universal influenza vaccines based on influenza virus M and NP genes</article-title><source>Infection</source><year>2014</year><volume>42</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s15010-013-0546-4</pub-id><?supplied-pmid 24178189?><pub-id pub-id-type="pmid">24178189</pub-id></element-citation></ref><ref id="B127-viruses-12-00276"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berthoud</surname><given-names>T.K.</given-names></name><name><surname>Hamill</surname><given-names>M.</given-names></name><name><surname>Lillie</surname><given-names>P.J.</given-names></name><name><surname>Hwenda</surname><given-names>L.</given-names></name><name><surname>Collins</surname><given-names>K.A.</given-names></name><name><surname>Ewer</surname><given-names>K.J.</given-names></name><name><surname>Milicic</surname><given-names>A.</given-names></name><name><surname>Poyntz</surname><given-names>H.C.</given-names></name><name><surname>Lambe</surname><given-names>T.</given-names></name><name><surname>Fletcher</surname><given-names>H.A.</given-names></name><etal/></person-group><article-title>Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>52</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq015</pub-id><?supplied-pmid 21148512?><pub-id pub-id-type="pmid">21148512</pub-id></element-citation></ref><ref id="B128-viruses-12-00276"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Co</surname><given-names>M.D.T.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Ennis</surname><given-names>F.A.</given-names></name><name><surname>Terajima</surname><given-names>M.</given-names></name></person-group><article-title>Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>215</volume><fpage>818</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw629</pub-id><pub-id pub-id-type="pmid">28011910</pub-id></element-citation></ref><ref id="B129-viruses-12-00276"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carragher</surname><given-names>D.M.</given-names></name><name><surname>Kaminski</surname><given-names>D.A.</given-names></name><name><surname>Moquin</surname><given-names>A.</given-names></name><name><surname>Hartson</surname><given-names>L.</given-names></name><name><surname>Randall</surname><given-names>T.D.</given-names></name></person-group><article-title>A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>4168</fpage><lpage>4176</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.6.4168</pub-id><?supplied-pmid 18768874?><pub-id pub-id-type="pmid">18768874</pub-id></element-citation></ref><ref id="B130-viruses-12-00276"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florek</surname><given-names>N.W.</given-names></name><name><surname>Weinfurter</surname><given-names>J.T.</given-names></name><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Brewoo</surname><given-names>J.N.</given-names></name><name><surname>Powell</surname><given-names>T.D.</given-names></name><name><surname>Young</surname><given-names>G.R.</given-names></name><name><surname>Das</surname><given-names>S.C.</given-names></name><name><surname>Hatta</surname><given-names>M.</given-names></name><name><surname>Broman</surname><given-names>K.W.</given-names></name><name><surname>Hungnes</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>13418</fpage><lpage>13428</lpage><pub-id pub-id-type="doi">10.1128/JVI.01219-14</pub-id><pub-id pub-id-type="pmid">25210172</pub-id></element-citation></ref><ref id="B131-viruses-12-00276"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderven</surname><given-names>H.A.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Ana-Sosa-Batiz</surname><given-names>F.</given-names></name><name><surname>Nguyen</surname><given-names>T.H.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Wines</surname><given-names>B.</given-names></name><name><surname>Hogarth</surname><given-names>P.M.</given-names></name><name><surname>Tilmanis</surname><given-names>D.</given-names></name><name><surname>Reynaldi</surname><given-names>A.</given-names></name><name><surname>Parsons</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Fc functional antibodies in humans with severe H7N9 and seasonal influenza</article-title><source>JCI Insight</source><year>2017</year><volume>2</volume><pub-id pub-id-type="doi">10.1172/jci.insight.92750</pub-id></element-citation></ref><ref id="B132-viruses-12-00276"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horns</surname><given-names>F.</given-names></name><name><surname>Vollmers</surname><given-names>C.</given-names></name><name><surname>Croote</surname><given-names>D.</given-names></name><name><surname>Mackey</surname><given-names>S.F.</given-names></name><name><surname>Swan</surname><given-names>G.E.</given-names></name><name><surname>Dekker</surname><given-names>C.L.</given-names></name><name><surname>Davis</surname><given-names>M.M.</given-names></name><name><surname>Quake</surname><given-names>S.R.</given-names></name></person-group><article-title>Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching</article-title><source>Elife</source><year>2016</year><volume>5</volume><fpage>e16578</fpage><pub-id pub-id-type="doi">10.7554/eLife.16578</pub-id><pub-id pub-id-type="pmid">27481325</pub-id></element-citation></ref><ref id="B133-viruses-12-00276"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Ding</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Xie</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>K.</given-names></name></person-group><article-title>Vaccine based on antibody-dependent cell-mediated cytotoxicity epitope on the H1N1 influenza virus increases mortality in vaccinated mice</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2018</year><volume>503</volume><fpage>1874</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.07.129</pub-id><?supplied-pmid 30064910?><pub-id pub-id-type="pmid">30064910</pub-id></element-citation></ref><ref id="B134-viruses-12-00276"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>T.</given-names></name><name><surname>Okayama</surname><given-names>H.</given-names></name><name><surname>Ashizawa</surname><given-names>M.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name><name><surname>Aoto</surname><given-names>K.</given-names></name><name><surname>Saito</surname><given-names>M.</given-names></name><name><surname>Monma</surname><given-names>T.</given-names></name><name><surname>Ohki</surname><given-names>S.</given-names></name><name><surname>Shibata</surname><given-names>M.</given-names></name><name><surname>Takenoshita</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer</article-title><source>Oncol. Lett.</source><year>2018</year><volume>15</volume><fpage>2604</fpage><lpage>2610</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.7556</pub-id><?supplied-pmid 29434980?><pub-id pub-id-type="pmid">29434980</pub-id></element-citation></ref><ref id="B135-viruses-12-00276"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohrt</surname><given-names>H.E.</given-names></name><name><surname>Houot</surname><given-names>R.</given-names></name><name><surname>Marabelle</surname><given-names>A.</given-names></name><name><surname>Cho</surname><given-names>H.J.</given-names></name><name><surname>Osman</surname><given-names>K.</given-names></name><name><surname>Goldstein</surname><given-names>M.</given-names></name><name><surname>Levy</surname><given-names>R.</given-names></name><name><surname>Brody</surname><given-names>J.</given-names></name></person-group><article-title>Combination strategies to enhance antitumor ADCC</article-title><source>Immunotherapy</source><year>2012</year><volume>4</volume><fpage>511</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.2217/imt.12.38</pub-id><?supplied-pmid 22642334?><pub-id pub-id-type="pmid">22642334</pub-id></element-citation></ref><ref id="B136-viruses-12-00276"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazar</surname><given-names>G.A.</given-names></name><name><surname>Dang</surname><given-names>W.</given-names></name><name><surname>Karki</surname><given-names>S.</given-names></name><name><surname>Vafa</surname><given-names>O.</given-names></name><name><surname>Peng</surname><given-names>J.S.</given-names></name><name><surname>Hyun</surname><given-names>L.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name><name><surname>Chung</surname><given-names>H.S.</given-names></name><name><surname>Eivazi</surname><given-names>A.</given-names></name><name><surname>Yoder</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Engineered antibody Fc variants with enhanced effector function</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>4005</fpage><lpage>4010</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508123103</pub-id><pub-id pub-id-type="pmid">16537476</pub-id></element-citation></ref><ref id="B137-viruses-12-00276"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming Lim</surname><given-names>C.</given-names></name><name><surname>Stephenson</surname><given-names>R.</given-names></name><name><surname>Salazar</surname><given-names>A.M.</given-names></name><name><surname>Ferris</surname><given-names>R.L.</given-names></name></person-group><article-title>TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24677</fpage><pub-id pub-id-type="doi">10.4161/onci.24677</pub-id><pub-id pub-id-type="pmid">23894722</pub-id></element-citation></ref><ref id="B138-viruses-12-00276"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roda</surname><given-names>J.M.</given-names></name><name><surname>Parihar</surname><given-names>R.</given-names></name><name><surname>Carson</surname><given-names>W.E.</given-names><suffix>3rd</suffix></name></person-group><article-title>CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>1619</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.3.1619</pub-id><pub-id pub-id-type="pmid">16034101</pub-id></element-citation></ref><ref id="B139-viruses-12-00276"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>A.W.</given-names></name><name><surname>Isitman</surname><given-names>G.</given-names></name><name><surname>Navis</surname><given-names>M.</given-names></name><name><surname>Kramski</surname><given-names>M.</given-names></name><name><surname>Center</surname><given-names>R.J.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><name><surname>Stratov</surname><given-names>I.</given-names></name></person-group><article-title>Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>7505</fpage><lpage>7510</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016048108</pub-id><pub-id pub-id-type="pmid">21502492</pub-id></element-citation></ref><ref id="B140-viruses-12-00276"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalls-Mantey</surname><given-names>A.</given-names></name><name><surname>Doria-Rose</surname><given-names>N.</given-names></name><name><surname>Klein</surname><given-names>R.</given-names></name><name><surname>Patamawenu</surname><given-names>A.</given-names></name><name><surname>Migueles</surname><given-names>S.A.</given-names></name><name><surname>Ko</surname><given-names>S.Y.</given-names></name><name><surname>Hallahan</surname><given-names>C.W.</given-names></name><name><surname>Wong</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>You</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>8672</fpage><lpage>8680</lpage><pub-id pub-id-type="doi">10.1128/JVI.00287-12</pub-id><pub-id pub-id-type="pmid">22674985</pub-id></element-citation></ref><ref id="B141-viruses-12-00276"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boge</surname><given-names>M.</given-names></name><name><surname>Wyss</surname><given-names>S.</given-names></name><name><surname>Bonifacino</surname><given-names>J.S.</given-names></name><name><surname>Thali</surname><given-names>M.</given-names></name></person-group><article-title>Membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>15773</fpage><lpage>15778</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.25.15773</pub-id><pub-id pub-id-type="pmid">9624176</pub-id></element-citation></ref><ref id="B142-viruses-12-00276"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegerlehner</surname><given-names>A.</given-names></name><name><surname>Schmitz</surname><given-names>N.</given-names></name><name><surname>Storni</surname><given-names>T.</given-names></name><name><surname>Bachmann</surname><given-names>M.F.</given-names></name></person-group><article-title>Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>5598</fpage><lpage>5605</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.9.5598</pub-id><?supplied-pmid 15100303?><pub-id pub-id-type="pmid">15100303</pub-id></element-citation></ref><ref id="B143-viruses-12-00276"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S.</given-names></name></person-group><article-title>The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine</article-title><source>Vaccines</source><year>2018</year><volume>6</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines6020027</pub-id><?supplied-pmid 29772781?><pub-id pub-id-type="pmid">29772781</pub-id></element-citation></ref><ref id="B144-viruses-12-00276"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosik</surname><given-names>I.</given-names></name><name><surname>Angeletti</surname><given-names>D.</given-names></name><name><surname>Gibbs</surname><given-names>J.S.</given-names></name><name><surname>Angel</surname><given-names>M.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Kosikova</surname><given-names>M.</given-names></name><name><surname>Nair</surname><given-names>V.</given-names></name><name><surname>Hickman</surname><given-names>H.D.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Brooke</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies</article-title><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><fpage>304</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1084/jem.20181624</pub-id><?supplied-pmid 30683737?><pub-id pub-id-type="pmid">30683737</pub-id></element-citation></ref><ref id="B145-viruses-12-00276"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Mohan</surname><given-names>T.</given-names></name><name><surname>Chang</surname><given-names>T.Z.</given-names></name><name><surname>Gonzalez</surname><given-names>G.X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Kwon</surname><given-names>Y.M.</given-names></name><name><surname>Kang</surname><given-names>S.M.</given-names></name><name><surname>Compans</surname><given-names>R.W.</given-names></name><name><surname>Champion</surname><given-names>J.A.</given-names></name><name><surname>Wang</surname><given-names>B.Z.</given-names></name></person-group><article-title>Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>359</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02725-4</pub-id><?supplied-pmid 29367723?><pub-id pub-id-type="pmid">29367723</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="viruses-12-00276-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schematic view of influenza virion. Hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2) are the proteins expressed on virus membrane. Trimeric HA protein consists of HA head and HA stalk. Viral ribonucleoprotein (vRNP) is composed of vRNA and nucleoprotein (NP, light purple). Viral polymerase complex includes polymerase basic proteins 1 (PB1, blue), 2 (PB2, tan) and acidic protein A (PA, light yellow). The matrix protein (M1) is a multi-functional protein involved in influenza virion assembly and infection.</p></caption><graphic xlink:href="viruses-12-00276-g001"/></fig><fig id="viruses-12-00276-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Antibody-dependent cellular cytotoxicity (ADCC)-epitopes in HA. Antibodies targeting HA stalk, as well as HA head including esterase domain and trimer interface, can induce potent ADCC <italic>in vitro</italic> and elicit broad-spectrum protection <italic>in vivo</italic>. The HA structure is generated using PyMOL. A/California 04/2009 HA (PDB code: 3UBE) is used as a representative HA structure to show the location of ADCC-epitopes. Influenza HA is a trimer with each monomer comprised of HA1(wheat), vestigial esterase domain (orange) and receptor binding domain (pink), and HA2 (palegreen). The remaining two monomers are shown in light blue. Sialic acid is colored cyan. Side view of the HA trimer surface is shown in (<bold>A</bold>), while the top view of the HA trimer interface is shown in the cartoon (<bold>B</bold>) and surface (<bold>C</bold>) modes. Besides, there are ADCC-Abs targeting HA head with unknown epitopes [<xref rid="B100-viruses-12-00276" ref-type="bibr">100</xref>].</p></caption><graphic xlink:href="viruses-12-00276-g002"/></fig><fig id="viruses-12-00276-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>ADCC- mediating antibodies (ADCC-Abs) targeting different influenza antigens. HA, NA and M2 are the surface-exposed proteins and they are capable of inducing ADCC-Abs. Antibodies targeting the conserved epitopes in these proteins confer broad protection against divergent viruses. NP expressed on the surface of the influenza-infected cell serves as a promising target for ADCC-Abs.</p></caption><graphic xlink:href="viruses-12-00276-g004"/></fig></floats-group></article>